Tetrahydrothiophene derivative and use thereof in medicine

MYPI2025004034A0Undetermined Publication Date: 2024-07-06HAISCO PHARMACEUTICAL GROUP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004034
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-14
Filing Date
2024-01-05
Publication Date
2024-07-06

AI Technical Summary

Technical Problem

Existing analgesics have problems such as significant side effects and poor selectivity when inhibiting Nav1.8 sodium ion channels, making it difficult to effectively reduce pain signal transmission.

Method used

A class of tetrahydrothiophene derivative compounds that selectively inhibit Nav1.8 were developed. Through specific structural design, the inhibitory activity and selectivity against Nav1.8 were improved, side effects were reduced, and good oral bioavailability and permeability were achieved.

Benefits of technology

This compound can effectively reduce pain signal transduction, has good analgesic activity and selectivity, reduces the occurrence of drug side effects, and is suitable for pain treatment in various animals.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A compound as represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or a cocrystal thereof, and an intermediate thereof, a preparation method therefor, and the use thereof in the preparation of a drug for treating pain.
Need to check novelty before this filing date? Find Prior Art

Description

A tetrahydrothiophene derivative and its application in medicine Technical Field

[0001] The present invention relates to a compound of general formula (I) or its stereoisomers, deuterated compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, as well as intermediates and preparation methods, and use of the compounds in preparing drugs for treating or alleviating pain. Background Art

[0002] Pain originates in nociceptors in the peripheral nervous system. These receptors convert thermal, mechanical, or chemical stimuli into nerve impulses (action potentials), which are transmitted via afferent nerve fibers to the cell bodies of neurons located in the dorsal root ganglia (DRG). Ultimately, these impulses are transmitted to higher neural centers, causing pain sensation. The generation and conduction of action potentials in neurons, in turn, rely on voltage-gated sodium channels (VGSCSs) on the cell membrane. When the cell membrane depolarizes, sodium channels activate and open, triggering an influx of sodium ions, further depolarizing the cell membrane and generating an action potential.

[0003] VGSCSs are composed of a pore-forming α-subunit (approximately 260 kDa) and an associated smaller β-subunit (30-40 kDa). The related α-subunit family consists of 10 members, 9 of which (Nav1.1-1.9) are voltage-gated. Nav1.8 is encoded by the gene SCN10A and is preferentially expressed in peripheral sensory neurons. It has been shown to shape action potentials in these neurons. Nav1.8 transcripts and proteins have been found in dorsal root ganglion (DRG) neurons. Nav1.8 has not been detected in non-neuronal tissues (such as heart and skeletal muscle) or in the central nervous system (including the brain and spinal cord).

[0004] The key role of Nav1.8 in pain signaling has been supported by multiple lines of evidence. Based on a series of animal studies and human genetic evidence, selective inhibition of Nav1.8 has the potential to become a novel analgesic therapy. Drugs targeting this target are currently in clinical trials.

[0005] Summary of the Invention

[0006] The purpose of the present invention is to provide a class of tetrahydrothiophene derivatives with inhibitory activity against Nav1.8. This class of compounds selectively inhibits Nav1.8 and can effectively reduce side effects. It has good analgesic activity and oral bioavailability, has good inhibitory activity and selectivity for hNav1.8, has excellent oral absorption performance in animals (such as mice, rats, dogs, and monkeys), weak inhibition of CYP enzymes, and good permeability.

[0007] The present invention provides a compound represented by general formula (I) or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.

[0008] In some embodiments, Selected from B is in trans with respect to the amide group in the ortho position;

[0009] In some embodiments, Selected from

[0010] In some embodiments, Selected from

[0011] In some embodiments, the compound represented by general formula (I) is selected from the group consisting of general formula (Ia), (Ib), (Ic), (Id), (Ie), (If)

[0012] In some embodiments, Q1 is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, C 5-10 carbocyclic group, 5- to 10-membered heterocyclic group or The aryl, heteroaryl, carbocyclic or heterocyclic group is optionally substituted by 1 to 5 R q replace;

[0013] In some embodiments, Q1 is selected from phenyl, benzo 4-6 Carbocyclic group, benzo 4 to 6 heterocyclic group, 5 to 6 membered heteroaryl, 8 to 10 membered heteroaryl or Preferably, Q1 is selected from phenyl, pyridyl or The Q1 is optionally replaced by 1 to 4 R q replace;

[0014] In some embodiments, Q1 is selected from Preferably, Q1 is selected from The Q1 is optionally replaced by 1 to 5 R q replace;

[0015] In some embodiments, R Q1 Selected from H, COOH, NR q1 R q2 、-C(=O)NR q1 R q2 、-S(=O)2NR q1 R q2 、OH、=O、-OR q1 、-C(=O)R q1 、-S(=O)2R q1 、-S(=O)(=NR q1 )R q2 or-P(=O)R q1 R q2 ;

[0016] In some embodiments, R Q1 Selected from H, COOH, NH2, -C(=O)NH2, -S(=O)2NH2, OH, =O, -S(=O)2CH3, -S(=O)2-cyclopropyl, -S(=O)(=NH)CH3, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl);

[0017] In some embodiments, Selected from The Q1 is optionally replaced by 1 to 3 R q replace;

[0018] In some embodiments, Selected from R Q1 Selected from COOH, -C(=O)NH2, -S(=O)2NH2, -S(=O)2CH3, -S(=O)(=NH)CH3, -P(=O)(CH3)2, R qa Selected from -CH2OH, R q Selected from F, Cl or methyl;

[0019] In some embodiments, R Q1 When selected from H, the Q1 is 1 to 5 R q Replaced with at least 1 R q Selected from R qa , Rqa Selected from -CH2OH, -CF2CH2OH, NH2, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl);

[0020] In some embodiments, R qa Selected from -CH2OH;

[0021] In some embodiments, Selected from The Q1 is optionally replaced by 1 to 3 R q replace;

[0022] In some embodiments, R q1 、R q2 Each independently selected from H, C 1-6 Alkyl, C 3-6 Carbocyclic group, 4 to 7 membered heterocyclic group, said alkyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;

[0023] Alternatively, R q1 、R q2 directly connected to form a 4- to 7-membered heterocyclic group, wherein the heterocyclic ring is optionally substituted by 1 to 4 R k replace;

[0024] In some embodiments, R q1 、R q2 Each independently selected from H, C 1-4 Alkyl, C 3-6 Carbocyclic group, 4 to 7 membered heterocyclic group, said alkyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;

[0025] Alternatively, R q1 、R q2 directly connected to form a 4- to 7-membered heterocyclic group, wherein the heterocyclic ring is optionally substituted by 1 to 4 R k replace;

[0026] In some embodiments, R q1 、R q2 Each independently selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or cyclopentyl, wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted by 1 to 4 R k replace;

[0027] In some embodiments, B is selected from C6-10 Aryl, 5- to 10-membered heteroaryl, C 5-10 Carbocyclic group, 5 to 10 membered heterocyclic group, the aryl, heteroaryl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R B replace;

[0028] In some embodiments, B is selected from phenyl, benzo 4-6 Carbocyclic group, benzo 4 to 6 heterocyclic group, 5 to 6 membered heteroaryl, 8 to 10 membered heteroaryl, wherein B is optionally substituted by 1 to 4 R B replace;

[0029] In some embodiments, B is selected from phenyl, The B is optionally replaced by 1 to 4 R B replace;

[0030] In some embodiments, B is selected from or phenyl, said B is optionally replaced by 1 to 4 R B replace;

[0031] In some embodiments, B is selected from Preferred

[0032] In some embodiments, R 1 、R 2 Each independently selected from H, halogen, CN, OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-6 Carbocyclic group, 3 to 7 membered heterocyclic group, the alkyl, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H;

[0033] In some embodiments, R 1 、R 2 Each independently selected from H, halogen, CN, OH, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 3-6Carbocyclic group, 3 to 7 membered heterocyclic group, the alkyl, alkenyl, alkynyl, carbocyclic or heterocyclic ring is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H;

[0034] In some embodiments, R 1 、R 2 Each independently selected from H, F, Cl, Br, cyano, methyl, ethyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl, wherein the methyl, ethyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H;

[0035] In some embodiments, R 1 、R 2 Each is independently selected from H, methyl, ethyl, CH2F, CHF2, CF3, provided that R 1 、R 2 Not at the same time H;

[0036] In some embodiments, R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, halogen, CN, OH, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7 Carbocyclic group, -OC 3-7 Carbocyclyl, 3- to 7-membered heterocyclyl, or -P(=O)R q1 R q2 The alkyl, alkenyl, alkynyl, carbocyclic or heterocyclic group is optionally substituted by 1 to 4 R k replace;

[0037] In some embodiments, R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, halogen, CN, OH, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 3-7 Carbocyclic group, -OC 3-7 Carbocyclyl, 3- to 7-membered heterocyclyl, or -P(=O)R q1 R q2 The alkyl, alkenyl, alkynyl, carbocyclic or heterocyclic group is optionally substituted by 1 to 4 R k replace;

[0038] In some embodiments, R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, F, Cl, Br, cyano, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropyloxy, methylthio, cyclopropyl, cyclopropyloxy, cyclobutyl, vinyl, ethynyl, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl), wherein the methyl, ethyl, isopropyl, methoxy, ethoxy, isopropyloxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl is optionally substituted by 1 to 4 R k replace;

[0039] In some embodiments, R 3 、R 4 Each independently selected from H, methyl, ethyl, CH2F, CHF2, CF3;

[0040] In some embodiments, R q 、R B Each independently selected from H, F, Cl, Br, cyano, CH2F, CHF2, CF3, -OCH2F, -OCHF2, -OCF3, -OCD3, methyl, -S-methyl, -S-CF3, ethyl, isopropyl, ethynyl, methoxy, ethoxy, isopropyloxy, propyloxy, cyclopropyl, -O-cyclopropyl, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl), wherein the methyl, ethyl, isopropyl, ethynyl, methoxy, ethoxy, isopropyloxy, propyloxy, cyclopropyl is optionally substituted by 1 to 4 R k replace;

[0041] In some embodiments, R B Each is independently selected from F, Cl, Br, cyano, CH2F, CHF2, CF3, -OCH2F, -OCHF2, -OCF3, -OCD3, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropyloxy, propyloxy, cyclopropyl, -O-cyclopropyl;

[0042] In some embodiments, R q Each independently selected from H, F, Cl, Br, cyano, CH2F, CHF2, CF3, -OCH2F, -OCHF2, -OCF3, -OCD3, methyl, -S-methyl, -S-CF3, ethyl, isopropyl, ethynyl, methoxy, ethoxy, isopropyloxy, propyloxy, cyclopropyl, -O-cyclopropyl, -CH2OH, -CF2CH2OH;

[0043] In some embodiments, R q Each independently selected from F, Cl, Br, cyano, CH2F, CHF2, CF3;

[0044] In some embodiments, any one of R q Selected from R qa ;

[0045] In some embodiments, R k Selected from deuterium, =O, halogen, CN, OH, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC 3-6 Carbocyclic group, -O-3 to 7 membered heterocyclic group, -NH-C 3-6 Carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 1-4 Alkylene-C 3-6 Carbocyclic group, -C 1-4 Alkylene-3 to 7 membered heterocyclic group, C 3-6 Carbocyclic group, 3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;

[0046] In some embodiments, R k Selected from deuterium, =O, halogen, CN, OH, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -OC 3-6Carbocyclic group, -O-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0047] In some embodiments, R k is selected from deuterium, =O, F, Cl, Br, I, CN, OH, NH2, NH(CH3), NH(CH2CH3), N(CH3)2, N(CH2CH3)2, methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0048] In some embodiments, R k Selected from deuterium, F, Cl, Br, I, CN, OH, -CH2OH, methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.

[0049] As a first embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0050] Q1 is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, C 5-10 carbocyclic group, 5- to 10-membered heterocyclic group or The aryl, heteroaryl, carbocyclic or heterocyclic group is optionally substituted by 1 to 5 R q replace;

[0051] R Q1 Selected from H, COOH, NR q1 R q2 、-C(=O)NR q1 R q2 、-S(=O)2NR q1 R q2 、OH、=O、-OR q1 、-C(=O)Rq1 、-S(=O)2R q1 、-S(=O)(=NR q1 )R q2 or-P(=O)R q1 R q2 ;

[0052] R q1 、R q2 Each independently selected from H, C 1-6 Alkyl, C 3-6 Carbocyclic group, 4 to 7 membered heterocyclic group, said alkyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;

[0053] Alternatively, R q1 、R q2 directly connected to form a 4- to 7-membered heterocyclic group, wherein the heterocyclic ring is optionally substituted by 1 to 4 R k replace;

[0054] B is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, C 5-10 Carbocyclic group, 5 to 10 membered heterocyclic group, the aryl, heteroaryl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R B replace;

[0055] R 1 、R 2 Each independently selected from H, halogen, CN, OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-6 Carbocyclic group, 3 to 7 membered heterocyclic group, the alkyl, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H;

[0056] R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, halogen, CN, OH, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7Carbocyclic group, -OC 3-7 Carbocyclyl, 3- to 7-membered heterocyclyl, or -P(=O)R q1 R q2 The alkyl, alkenyl, alkynyl, carbocyclic or heterocyclic group is optionally substituted by 1 to 4 R k replace;

[0057] R k Selected from deuterium, =O, halogen, CN, OH, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC 3-6 Carbocyclic group, -O-3 to 7 membered heterocyclic group, -NH-C 3-6 Carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 1-4 Alkylene-C 3-6 Carbocyclic group, -C 1-4 Alkylene-3 to 7 membered heterocyclic group, C 3-6 Carbocyclic group, 3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent.

[0058] As a second embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0059] R q1 、R q2 Each independently selected from H, C 1-4 Alkyl, C 3-6 Carbocyclic group, 4 to 7 membered heterocyclic group, said alkyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;

[0060] Alternatively, R q1 、R q2 directly connected to form a 4- to 7-membered heterocyclic group, which is optionally substituted by 1 to 4 R k replace;

[0061] Q1 is selected from phenyl, benzo 4-6 Carbocyclic group, benzo 4 to 6 heterocyclic group, 5 to 6 membered heteroaryl, 8 to 10 membered heteroaryl or Preferably, Q1 is selected from phenyl, pyridyl or The Q1 is optionally replaced by 1 to 4 R q replace;

[0062] B is selected from phenyl, benzo 4-6 Carbocyclic group, benzo 4 to 6 heterocyclic group, 5 to 6 membered heteroaryl, 8 to 10 membered heteroaryl, wherein B is optionally substituted by 1 to 4 R B replace;

[0063] R 1 、R 2 Each independently selected from H, halogen, CN, OH, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 3-6 Carbocyclic group, 3 to 7 membered heterocyclic group, the alkyl, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H;

[0064] R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, halogen, CN, OH, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 3-7 Carbocyclic group, -OC 3-7 Carbocyclyl, 3- to 7-membered heterocyclyl, or -P(=O)R q1 R q2 The alkyl, alkenyl, alkynyl, carbocyclic or heterocyclic group is optionally substituted by 1 to 4 R k replace;

[0065] R k Selected from deuterium, =O, halogen, CN, OH, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -OC 3-6Carbocyclic group, -O-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0066] The remaining groups are defined the same as in the first embodiment of the present invention.

[0067] As a third embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0068] R q1 、R q2 Each independently selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or cyclopentyl, wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted by 1 to 4 R k replace;

[0069] R 1 、R 2 Each independently selected from H, F, Cl, Br, cyano, methyl, ethyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl, wherein the methyl, ethyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H;

[0070] B is selected from or phenyl, preferably phenyl, The B is optionally replaced by 1 to 4 R B replace;

[0071] R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, F, Cl, Br, cyano, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropyloxy, methylthio, cyclopropyl, cyclopropyloxy, cyclobutyl, vinyl, ethynyl, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl), wherein the methyl, ethyl, isopropyl, methoxy, ethoxy, isopropyloxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl is optionally substituted by 1 to 4 R k Replacement; R kis selected from deuterium, =O, F, Cl, Br, I, CN, OH, NH2, NH(CH3), NH(CH2CH3), N(CH3)2, N(CH2CH3)2, methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0072] The remaining groups are defined the same as in the first or second embodiment of the present invention.

[0073] As a fourth embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0074] Q1 is selected from The Q1 is optionally replaced by 1 to 5 R q replace;

[0075] R 3 、R 4 Each independently selected from H, methyl, ethyl, CH2F, CHF2, CF3;

[0076] R 1 、R 2 Each is independently selected from H, methyl, ethyl, CH2F, CHF2, CF3, provided that R 1 、R 2 Not at the same time H;

[0077] R q 、R B Each independently selected from H, F, Cl, Br, cyano, CH2F, CHF2, CF3, -OCH2F, -OCHF2, -OCF3, -OCD3, methyl, -S-methyl, -S-CF3, ethyl, isopropyl, ethynyl, methoxy, ethoxy, isopropyloxy, cyclopropyl, -O-cyclopropyl, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl), wherein the methyl, ethyl, isopropyl, ethynyl, methoxy, ethoxy, isopropyloxy, cyclopropyl is optionally substituted by 1 to 4 R k replace;

[0078] R k Selected from deuterium, F, Cl, Br, I, CN, OH, -CH2OH, methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;

[0079] The remaining groups are defined the same as in the first, second or third embodiment of the present invention.

[0080] As a fifth embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0081] Selected from The Q1 is optionally replaced by 1 to 3 R q replace;

[0082] R qa Selected from -CH2OH, -CF2CH2OH, NH2, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl);

[0083] Preferably, Selected from The Q1 is optionally replaced by 1 to 3 R q replace;

[0084] B is selected from Preferred

[0085] The remaining groups are defined the same as in the first, second, third or fourth embodiment of the present invention.

[0086] As a sixth embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0087] The compound represented by the general formula (I) is selected from the group consisting of the general formulas (Ia), (Ib), (Ic), (Id), (Ie), (If)

[0088] The remaining groups are defined the same as in the first, second, third, fourth or fifth embodiment of the present invention.

[0089] As a seventh embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0090] Selected from

[0091] The remaining groups are defined the same as in the first, second, third, fourth or fifth embodiment of the present invention.

[0092] The present invention relates to the compound shown below or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from one of the structures shown below in Table E.

[0093] Table E

[0094] The present invention relates to a pharmaceutical composition comprising any of the above compounds or their stereoisomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals, and a pharmaceutically acceptable carrier.

[0095] The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of the above-mentioned compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, and a pharmaceutically acceptable carrier.

[0096] In some embodiments, the pharmaceutical composition of the present invention may be in the form of a unit preparation (the amount of the main drug in a unit preparation is also referred to as the "preparation strength").

[0097] As used herein, an "effective amount" or "therapeutically effective amount" refers to administering a sufficient amount of a compound disclosed herein to alleviate, to some extent, one or more symptoms of the disease or condition being treated (e.g., treating and / or alleviating pain). In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a compound disclosed herein required to provide a clinically significant reduction in disease symptoms.Examples of therapeutically effective amounts include, but are not limited to, 1-1500 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 2-600 mg, 3-600 mg, 4-600 mg, 5-600 mg, 6-600 mg, 10-600 mg, 20-600 mg, 25-600 mg, 30-600 mg, 40-600 mg, 50-600 mg, 60-600 mg, 70-600 mg, 75-600 mg, 80-600 mg, 90-600 mg, 100-600 mg, 200-600 mg, 1-500 mg, 2-500 mg, 3-500 mg, 4-500 mg, 5-500mg, 6-500mg, 10-500mg, 20-500mg, 25-500mg, 30-500mg, 40-500mg, 50-50 0mg, 60-500mg, 70-500mg, 75-500mg, 80-500mg, 90-500mg, 100-500mg, 125-500 mg, 150-500mg, 200-500mg, 250-500mg, 300-500mg, 400-500mg, 5-400mg, 10-40 0mg, 20-400mg, 25-400mg, 30-400mg, 40-400mg, 50-400mg, 60-400mg, 70-400mg, 75-400mg, 80-400mg, 90-400mg, 100-400mg, 125-400mg, 150-400mg, 200-400mg, 250-400mg, 300-400mg, 1-300mg, 2-300mg, 5-300 mg, 10-300mg, 20-300mg, 25-300mg, 30-300mg, 40-300mg, 50-300mg, 60-300mg, 70-300mg, 75-300mg, 80-300mg, 90-300mg, 100-30 0mg, 125-300mg, 150-300mg, 200-300mg, 250-300mg, 1-200mg, 2-200mg, 5-200mg, 10-200mg, 20-200mg, 25-200mg, 30-200mg, 40-2 00mg, 50-200mg, 60-200mg, 70-200mg, 75-200mg, 80-200mg, 90-200mg, 100-200mg, 125-200mg, 150-200mg, 80-1000mg, 80-800mg.

[0098] In some embodiments, the pharmaceutical composition includes but is not limited to 1-1000 mg, 20-800 mg, 40-800 mg, 40-400 mg, 25-200 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg , 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 300 mg, 320 mg, 400 mg, 480 mg, 500 mg, 600 mg, 640 mg, 840 mg of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.

[0099] A method for treating a disease in a mammal, comprising administering to a subject a therapeutically effective amount of a compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, preferably 1-1500 mg, wherein the disease is preferably the treatment or relief of pain.

[0100] A method for treating or alleviating a disease in a mammal, comprising administering to a subject a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof at a daily dose of 1-1000 mg / day, wherein the daily dose can be a single dose or divided doses. In some embodiments, the daily dose includes but is not limited to 10-1500 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-800 mg / day, 100-800 mg / day, 200-800 mg / day, 100-1500 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-800 mg / day, 100-800 mg / day, 200-800 mg / day, 100-1500 mg / day, 100-10 ... In some embodiments, daily doses include but are not limited to 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 100 mg / day, 200 mg / day, and in some embodiments, daily doses include but are not limited to 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 80 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 160 mg / day, 200 mg / day, 300 mg / day, 320 mg / day, 400 mg / day, 480 mg / day, 600 mg / day, 640 mg / day, 800 mg / day, and 1000 mg / day.

[0101] The present invention relates to a kit, which may include a composition in single-dose or multi-dose form, wherein the kit contains a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and the amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal is the same as the amount in the above-mentioned pharmaceutical composition.

[0102] The present invention relates to the use of any of the above compounds or their stereoisomers, deuterated substances, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals in the preparation of drugs for treating and / or alleviating pain.

[0103] The present invention relates to the use of the above-mentioned pharmaceutical composition in preparing medicines for treating and / or alleviating pain.

[0104] The amount of the compound of the invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof is in each case calculated as the free base.

[0105] Synthesis method 1:

[0106] The general formula (Z1) and the general formula (Z2) are subjected to Wittig reaction to obtain the corresponding general formula (Z3), the general formula (Z3) is subjected to addition reaction with ethyl mercaptoacetate to obtain the corresponding general formula (Z4), the general formula (Z4) is subjected to intramolecular ester condensation to obtain the corresponding general formula (Z5), the general formula (Z5) is protected by a protective group to obtain the corresponding general formula (Z6), the general formula (Z6) and the fragment (BX) are coupled to obtain the corresponding general formula (Z7), the general formula (Z7) is reduced to obtain the corresponding general formula (Z8), the general formula (Z8) and the amino fragment (R Q1 -Q1-NH2) is condensed to give the corresponding general formula (Ia').

[0107] X is halogen, boronic acid or boronic ester.

[0108] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[0109] The carbon, hydrogen, oxygen, sulfur, nitrogen, F, Cl, Br, and I involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur, or nitrogen involved in the groups and compounds of the present invention are optionally replaced by one or more of their corresponding isotopes, wherein the isotopes of carbon include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (D, also called heavy hydrogen), tritium (T, also called super tritium), oxygen isotopes include 16 O. 17 O and18 O, sulfur isotopes include 32 S. 33 S. 34 S and 36 S, nitrogen isotopes include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, chlorine isotopes include 35 Cl and 37 Isotopes of Cl, bromine include 79 Br and 81 Br.

[0110] "Halogen" refers to F, Cl, Br or I.

[0111] "Halogen-substituted" refers to substitution with F, Cl, Br or I, including but not limited to substitution with 1 to 10 substituents selected from F, Cl, Br or I, substitution with 1 to 6 substituents selected from F, Cl, Br or I, and substitution with 1 to 4 substituents selected from F, Cl, Br or I. "Halogen-substituted" is abbreviated as "halo".

[0112] "Alkyl" refers to a substituted or unsubstituted straight-chain or branched saturated aliphatic hydrocarbon group, including but not limited to alkyl groups of 1 to 20 carbon atoms, alkyl groups of 1 to 8 carbon atoms, alkyl groups of 1 to 6 carbon atoms, and alkyl groups of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof; alkyl groups appearing herein have the same definition as this one. Alkyl groups can be monovalent, divalent, trivalent, or tetravalent.

[0113] "Alkylene" refers to substituted or unsubstituted straight-chain and branched divalent saturated hydrocarbon groups, including -(CH2) v -(v is an integer from 1 to 10), examples of alkylene include but are not limited to methylene, ethylene, propylene and butylene.

[0114] "Cycloalkyl" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon radical, typically having 3 to 10 carbon atoms, non-limiting examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Cycloalkyl groups as used herein are as defined above. Cycloalkyl groups can be monovalent, divalent, trivalent, or tetravalent.

[0115] "Heterocycloalkyl" refers to a substituted or unsubstituted saturated cyclic hydrocarbon group containing heteroatoms, including but not limited to 3 to 10 atoms, 3 to 8 atoms, including 1 to 3 heteroatoms selected from N, O or S. The N and S optionally substituted in the heterocycloalkyl ring can be oxidized to various oxidation states. The heterocycloalkyl group can be attached to a heteroatom or a carbon atom, can be attached to an aromatic ring or a non-aromatic ring, can be connected to a bridged ring or a spirocycle, and non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolanyl, dioxane, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazinyl, morpholinyl, hexahydropyrimidinyl, piperazinyl. The heterocycloalkyl group can be monovalent, divalent, trivalent or tetravalent.

[0116] "Alkenyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon double bonds, with a backbone of 2 to 10, 2 to 6 or 2 to 4 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 2- Methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene, and 1,4-hexadiene; alkenyl groups appearing herein have the same definition as this one. Alkenyl groups may be monovalent, divalent, trivalent, or tetravalent.

[0117] "Alkynyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon triple bonds, including but not limited to 2 to 10 carbon atoms, 2 to 6 carbon atoms, 2 to 4 carbon atoms in the backbone chain. Examples of alkynyl groups include but are not limited to ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- Alkynyl groups include methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, and 4-decynyl. Alkynyl groups may be monovalent, divalent, trivalent, or tetravalent.

[0118] "Alkoxy" refers to a substituted or unsubstituted -O-alkyl group. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropyloxy, and cyclobutyloxy.

[0119] "Carbocyclyl" or "carbocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring, or a 10-15 membered tricyclic ring system, and the carbocyclyl can be attached to the aromatic or non-aromatic ring, which can be optionally a monocyclic ring, a bridged ring, or a spirocyclic ring. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, a benzene ring, a naphthalene ring, "Carbocyclyl" or "carbocycle" can be monovalent, divalent, trivalent, or tetravalent.

[0120] "Heterocyclyl" or "heterocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring or a 10-15 membered tricyclic ring system, and contains one or more (including but not limited to 2, 3, 4 or 5) heteroatoms selected from N, O or S. The N and S selectively substituted in the heterocyclyl ring can be oxidized to various oxidation states. The heterocyclyl can be attached to a heteroatom or a carbon atom, the heterocyclyl can be attached to an aromatic ring or a non-aromatic ring, and the heterocyclyl can be connected to a bridged ring or a spirocycle. Non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, 1,3-dioxolane, 1,4-dioxolane, 1,3-dioxahexanyl, azepanyl, pyridyl, furanyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithiazyl, dihydrofuranyl, dihydropyranyl, dithiolanyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, benzodihydrofuranyl, pyrrolyl, pyrazolyl, Thiazolyl, oxazolyl, pyrazinyl, indazolyl, benzothiophenyl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, piperazinyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonyl, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl, oxaspiro[3.3]heptanyl, "Heterocyclyl" or "heterocycle" can be monovalent, divalent, trivalent or tetravalent.

[0121] "Heteroaryl" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group containing 1 to 5 heteroatoms or groups containing heteroatoms (including but not limited to N, O or S(=O)n, n is 0, 1, 2), and the number of ring atoms in the heteroaromatic ring is but not limited to 5 to 15, 5 to 10 or 5 to 6. Non-limiting examples of heteroaryl include but are not limited to pyridyl, furyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazole, benzimidazole, benzopyridine, pyrrolopyridine, etc. The heteroaryl ring can be fused to a saturated or unsaturated carbocyclic ring or heterocyclic ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include When heteroaryl appears in this document, its definition is consistent with this definition. Heteroaryl can be monovalent, divalent, trivalent or tetravalent. When it is divalent, trivalent or tetravalent, the attachment point is located on the heteroaryl ring.

[0122] "Substituted" or "substituted" refers to substitution by one or more (including but not limited to 2, 3, 4 or 5) substituents, including but not limited to H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxyl, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclic, bridged, spiro, cycloalkyl, hydroxyalkyl, =O, carbonyl, aldehyde, carboxylic acid, formate, -(CH2), m -C(=O)-R a 、-O-(CH2) m -C(=O)-R a 、-(CH2) m -C(=O)-NR b R c 、-(CH2) m S(=O) n R a 、-(CH2) m -alkenyl-R a , OR d or -(CH2) m -alkynyl-R a (wherein m and n are 0, 1 or 2), arylthio, thiocarbonyl, silyl or -NR b R c etc., where R b With R c R is independently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, b With R c Can form a five- or six-membered cycloalkyl or heterocyclic group, R a With R d Each is independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring or paracyclic group.

[0123] "1 to X substituents selected from..." means substituted by 1, 2, 3, ..., X substituents selected from ..., where X is any integer from 1 to 10. For example, "1 to 4 R k "Substituted" means replaced by 1, 2, 3 or 4 R k Substitution. For example, "substituted with 1 to 5 substituents selected from..." means substituted with 1, 2, 3, 4, or 5 substituents selected from..." For example, "a heterobridged ring is optionally substituted with 1 to 4 substituents selected from D or F" means that the heterobridged ring is optionally substituted with 1, 2, 3, or 4 substituents selected from D or F.

[0124] An XY-membered ring (X is an integer, 3≤X<Y, and Y is any integer between 4 and 12) includes rings with X, X+1, X+2, X+3, X+4, ..., Y members. Rings include heterocyclic rings, carbocyclic rings, aromatic rings, aryl groups, heteroaryl groups, cycloalkyl groups, heteromonocyclic rings, heterocyclic rings, heterospirocyclic rings, or heterobridged rings. For example, "4-7-membered heteromonocyclic ring" refers to a 4-, 5-, 6-, or 7-membered heteromonocyclic ring, and "5-10-membered heterocyclic ring" refers to a 5-, 6-, 7-, 8-, 9-, or 10-membered heterocyclic ring.

[0125] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs and instances where it does not. For example, "alkyl optionally substituted with F" means that the alkyl group may but need not be substituted with F, and the description includes instances where the alkyl group is substituted with F and instances where the alkyl group is not substituted with F.

[0126] "Pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" refers to a salt of the compound of the present invention that retains the biological effectiveness and properties of the free acid or free base, and the free acid is obtained by reacting with a non-toxic inorganic base or organic base, or the free base is obtained by reacting with a non-toxic inorganic acid or organic acid.

[0127] "Pharmaceutical composition" refers to a mixture of one or more compounds of the present invention, or stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals thereof, and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients and / or one or more other therapeutic agents.

[0128] "Carrier" refers to a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.

[0129] "Preparation specifications" refers to the weight of the main drug contained in each vial, tablet or other unit preparation.

[0130] "Animal" is meant to include mammals, such as humans, companion animals, zoo animals, and livestock, preferably humans, horses, or dogs.

[0131] "Stereoisomers" refer to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers, and conformational isomers.

[0132] "Tautomers" refer to functional group isomers produced by the rapid movement of an atom in a molecule between two positions, such as keto-enol isomers and amide-imino alcohol isomers. DETAILED DESCRIPTION

[0133] The following examples illustrate the technical solutions of the present invention in detail, but the protection scope of the present invention includes but is not limited to them.

[0134] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or / and mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker Avance III 400 and Bruker Avance 300 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). The internal standard was tetramethylsilane (TMS).

[0135] MS was determined using (Agilent 6120B (ESI) and Agilent 6120B (APCI));

[0136] HPLC determination was performed using an Agilent 1260DAD high-pressure liquid chromatograph (Zorbax SB-C18 100 × 4.6 mm, 3.5 μM);

[0137] Prep-HPLC preparation (condition 1): Instrument: Waters AutoP; Preparative column: Sunfire C18 (19 mm × 250 mm). Preparation: Dissolve the sample in methanol and filter through a 0.45 μm filter to prepare the sample solution. Mobile phase: acetonitrile / water (0.1% trifluoroacetic acid); gradient elution from 35% to 80% acetonitrile, flow rate: 15 mL / min, elution time: 20 minutes.

[0138] Prep-HPLC conditions (condition 2): Instrument: Waters 2767 preparative liquid phase; Preparative column: SunFire C18 (19 mm × 250 mm). Samples were dissolved in DMF and filtered through a 0.45 μm filter to prepare the sample solution. Mobile phase: acetonitrile / water (0.1% trifluoroacetic acid); gradient elution from 10% to 70% acetonitrile; flow rate: 17 mL / min; elution time: 20 minutes.

[0139] Prep-HPLC (neutral preparative): Instrument: Waters AutoP, preparative column: XSelect C18 (19 mm × 250 mm). Preparation: Dissolve the crude product in methanol and filter through a 0.45 μm filter to prepare the sample solution. Mobile phase: acetonitrile / water (5 mM ammonium acetate); gradient elution, acetonitrile content 30%-80%, flow rate: 15 mL / min, elution time: 20 minutes.

[0140] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications of the silica gel plates used in thin layer chromatography (TLC) are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm.

[0141] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

[0142] In order to accomplish the purpose of the present invention, the compounds used in the reactions described herein are prepared according to organic synthesis techniques known to those skilled in the art, starting from commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources, including Shanghai Aladdin Biochemical Technology Co., Ltd., Shanghai McLean Biochemical Technology Co., Ltd., Sigma-Aldrich, Alfa Aesar (China) Chemical Co., Ltd., TCI (Shanghai) Chemical Industry Development Co., Ltd., Anage Chemical, Shanghai Titan Technology Co., Ltd., Kelon Chemical, Bailingwei Technology Co., Ltd., etc.

[0143] TCFH: tetramethylchlorouronium hexafluorophosphate; THF: tetrahydrofuran; DMF: N,N-dimethylformamide; DIPEA: N,N-diisopropylethylamine; HATU: CAS 148893-10-1; T3P (50% wt in EtOAc): CAS 68957-94-8

[0144] Retention time: Unless otherwise specified in the examples, it represents the retention time corresponding to the analytical method.

[0145] Example 1: Preparation of Compound 1-1a and Compound 1-1b

[0146] Step 1: Preparation of compound 1b

[0147] 1a-1 (30.96 g, 129.95 mmol) was dissolved in tetrahydrofuran (130 mL) under an ice bath. Sodium hydride (5.20 g, 130 mmol) was added portionwise. The mixture was reacted under a nitrogen atmosphere and ice bath for 30 minutes. 1a (11.20 g, 100 mmol) was dissolved in tetrahydrofuran (20 mL) and added dropwise to the reaction system. The temperature was naturally raised to room temperature under a nitrogen atmosphere and the reaction was allowed to proceed for 18 hours. Under an ice bath, 1N hydrochloric acid was slowly added dropwise to the reaction system until the pH reached 7-8. The reaction system was extracted with diethyl ether (150 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated (at room temperature) to obtain the crude product. The crude product was purified by silica gel column chromatography to afford 1b (14.1 g, 71.88% yield, E / Z configuration mixture).

[0148] Step 2: Preparation of compound 1c

[0149] Under ice-cooling, 1b-1 (8.63 g, 71.88 mmol) was added to a round-bottom flask. Piperidine (1.22 g, 14.38 mmol) was added dropwise, followed by 1b (6.0 g, 71.88 mmol). The mixture was reacted at 50°C under nitrogen for 24 h. The reaction was quenched with 0.1N hydrochloric acid (100 mL) under ice-cooling, and extracted with diethyl ether (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated (at 25°C) to afford crude 1c, which was purified by silica gel column chromatography to afford 1c (6.3 g, 27.96% yield).

[0150] LC-MS m / z=317.1[M+H] +

[0151] Step 3: Preparation of compound 1d

[0152] On ice, 1c (6.3 g, 19.92 mmol) was dissolved in diethyl ether (120 mL). Under nitrogen, potassium tert-butoxide (2.91 g, 25.90 mmol) was slowly added dropwise to the system. The mixture was allowed to react on ice for 2 h. Glacial acetic acid (1.56 mL) and water (100 mL) were added to the reaction system to quench the reaction. The mixture was extracted with diethyl ether (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 1d.

[0153] Step 4: Preparation of compound 1e

[0154] 1d (4.05 g, 15 mmol) was dissolved in dichloromethane (40 mL) and precooled at -78°C for 15 minutes. N,N-diisopropylethylamine (2.32 g, 17.99 mmol) was added dropwise under a nitrogen atmosphere. Trifluoromethanesulfonic anhydride (4.23 g, 15 mmol) dissolved in dichloromethane (10 mL) was slowly added dropwise to the system. After addition, the reaction was continued at -78°C for 2 hours. Under an ice bath, saturated aqueous sodium bicarbonate (50 mL) was slowly added to the reaction system to quench the reaction. The mixture was extracted with dichloromethane (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford 1e (5.2 g, 86.16% yield).

[0155] Step 5: Preparation of compound 1f

[0156] 1e (5.2 g, 12.92 mmol) was dissolved in toluene (50 mL), followed by the addition of 1e-1 (2.67 g, 14.21 mmol) and Pd(PPh3)4 (0.75 g, 0.65 mmol). A 2M aqueous solution of potassium phosphate (8.23 g, 38.71 mmol) was added to the system, and the reaction was incubated at 100°C for 6 h under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with ethyl acetate (10 mL × 2). The filtrate was separated and the organic phase was collected. The aqueous phase was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford 1f (5.1 g, 99.59% yield).

[0157] LC-MS m / z=397.1[M+H] +

[0158] Step 6: Preparation of compounds 1g-1a and 1g-1b

[0159] 1f (3.7 g, 9.33 mmol) was dissolved in methanol (50 mL), and palladium on carbon (1.99 g, 18.56 mmol) was added. After addition, the mixture was reacted at room temperature under a hydrogen atmosphere, pressurized to 2 MPa, for 24 h. The reaction mixture was filtered and the filtrate was concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to afford a mixture of 1g-1a and 1g-1b (1.02 g, 27.44% yield). A mixture of unreacted starting materials 1f-2a and 1f-2b (0.148 g, 4.00% yield) was also recovered.

[0160] A mixture of 1g-1a and 1g-1b:

[0161] LC-MS m / z=399.4[M+H] +

[0162] 1 H NMR (400MHz, CDCl3): δ6.96-6.90(m,1H),6.88-6.79(m,1H),4.08-4.01(m,4H),3.94-3. 80(m,2H),3.77-3.68(m,1H),3.49-3.37(m,1H),1.59(s,3H),1.02(t,3H),0.96(d,3H).

[0163] Mixture of 1f-2a and 1f-2b:

[0164] LC-MS m / z=397.1[M+H] +

[0165] 1H NMR (400MHz, CDCl3): δ6.90-6.81(m,1H),6.77-6.71(m,1H),4.13-4.04(m,2H) ,3.92(d,3H),3.42-3.34(m,1H),1.77(s,3H),1.13(t,3H),1.09-1.04(m,3H).

[0166] Step 7: Preparation of compounds 1h-1a and 1h-1b

[0167] Under a nitrogen atmosphere and an ice bath, a mixture of 1g-1a and 1g-1b (1.02 g, 2.56 mmol) was dissolved in tetrahydrofuran (25 mL). The mixture was pre-cooled for 15 minutes, and potassium tert-butoxide (0.95 g, 8.46 mmol) was slowly added dropwise to the system (internal temperature <13°C). After the addition, the reaction was continued on ice for 2 hours. Under an ice bath, 1N hydrochloric acid was slowly added dropwise to the system (internal temperature <13°C) until the pH reached 1. Water (10 mL) was then added, and the mixture was extracted with ethyl acetate (25 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a mixture of 1h-1a and 1h-1b.

[0168] LC-MS m / z=369.0[MH] -

[0169] Step 8: Preparation of compounds 1i-1a and 1i-1b

[0170] A mixture of 1h-1a and 1h-1b (0.90 g, 2.44 mmol) was dissolved in DMF (20 mL). 1h-2 (0.56 g, 3.68 mmol), TCFH (1.37 g, 4.88 mmol), and N-methylimidazole (0.40 g, 4.88 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Water (20 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined and washed with saturated brine (90 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain a mixture of 1i-1a and 1i-1b (0.526 g, 42.65% yield).

[0171] LC-MS m / z=505.2[M+H] +

[0172] Step 9: Preparation of Compound 1-1a and Compound 1-1b

[0173] A mixture of 1i-1a and 1i-1b (0.52 g, 1.04 mmol) was dissolved in 7 M methanolic ammonia (5 mL) and allowed to react at room temperature for 18 h. The reaction mixture was concentrated to obtain a crude product, which was then purified by silica gel column chromatography to afford a mixture of compounds 1-1a and 1-1b (0.38 g, 74.50% yield).

[0174] LC-MS m / z=490.2[M+H] + ;

[0175] 1 H NMR (400MHz, DMSO-d6): δ10.74(s,1H),8.45(d,1H),8.14(d,1H),8.07-7.99(m,1H),7.67-7.63(m,1H),7.62- 7.56(m,1H),7.21-7.12(m,2H),4.47(d,1H),4.00-3.82(m,4H),2.84-2.72(m,1H),1.61(s,3H),0.83(d,3H).

[0176] Example 2: Preparation of Compound 1-2a and Compound 1-2b

[0177] Step 1: Preparation of compounds 1g-2a and 1g-2b

[0178] A mixture of 1f-2a and 1f-2b (0.148 g, 0.38 mmol) was dissolved in methanol (10 mL), and palladium on carbon (0.15 g, 1.41 mmol) was added. After addition, the mixture was reacted at 90°C under a hydrogen atmosphere at a pressure of 2.5 MPa for 24 h. The reaction mixture was filtered and the filtrate was concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford a mixture of 1g-2a and 1g-2b (0.052 g, 34.35% yield).

[0179] Step 2: Preparation of compounds 1h-2a and 1h-2b

[0180] Under a nitrogen atmosphere and an ice bath, a mixture of 1g-2a and 1g-2b (0.052 g, 0.13 mmol) was dissolved in tetrahydrofuran (5 mL) and pre-cooled for 15 minutes. Potassium tert-butoxide (0.048 g, 0.43 mmol) was slowly added dropwise to the system (internal temperature <13°C). After addition, the mixture was allowed to react on ice for 2 hours. Under an ice bath, 1N hydrochloric acid was slowly added dropwise to the system (internal temperature <13°C) until pH = 1. Water (5 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a mixture of 1h-2a and 1h-2b.

[0181] LC-MS m / z=369.0[MH]-

[0182] Step 3: Preparation of compounds 1i-2a and 1i-2b

[0183] A mixture of 1h-2a and 1h-2b (0.048 g, 0.13 mmol) was dissolved in DMF (3 mL). 1h-2 (0.03 g, 0.20 mmol), TCFH (0.073 g, 0.26 mmol), and N-methylimidazole (0.022 g, 0.26 mmol) were added sequentially, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Water (10 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined and washed with saturated brine (30 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain a mixture of 1i-2a and 1i-2b (0.01 g, 15.25% yield).

[0184] LC-MS m / z=505.2[M+H] +

[0185] Step 4: Preparation of Compound 1-2a and Compound 1-2b

[0186] A mixture of compounds 1i-2a and 1i-2b (0.01 g, 0.02 mmol) was dissolved in 7 M methanolic ammonia (3 mL) and allowed to react at room temperature for 8 h. The reaction mixture was concentrated to obtain a crude product, which was then purified by silica gel column chromatography to afford a mixture of compounds 1-2a and 1-2b (0.006 g, 61.91% yield).

[0187] LC-MS m / z=490.2[M+H] + ;

[0188] 1 H NMR (400MHz, DMSO-d6): δ10.92(s,1H),8.47(d,1H),8.17(d,1H),8.06-8.00(m,1H),7.70-7.64(m,1H),7.63-7.57(m,1 H),7.22-7.06(m,2H),4.86(d,1H),4.54-4.46(m,1H),4.01(d,3H),2.66-2.58(m,1H),1.85(s,3H),0.83-0.75(m,3H).

[0189] SFC preparation conditions:

[0190] Instrument: Waters 150 Prep-SFC C, Preparative Column: Chiralcel OX Column. Preparation: Dissolve the crude product in acetonitrile to a 10 mg / ml sample solution. Mobile phase: CO2 / methanol, 30% methanol; Elution time: 8 min.

[0191] A mixture of 504 mg of compounds 1-2a and 1-2b was prepared by SFC and lyophilized to give compounds 1-2P1 (193.8 mg, retention time: 1.137 min) and 1-2P2 (218 mg, retention time: 1.526 min). Chiral analysis method: (Instrument: SHIMADZU LC-30 AD sf, Chiralcel OX Column. Preparation: The crude product was dissolved in acetonitrile to prepare a sample solution. Mobile phase: carbon dioxide / 0.05% DEA in methanol. Elution gradient: 5%-40%; flow rate: 3.0 mL / min, elution time: 3 min).

[0192] Compound 1-2P1 has a structure that is either Formula 1-2a or 1-2b, and is an enantiomer of Compound 1-2P2. That is, when Compound 1-2P1 has a structure that is Formula 1-2a, Compound 1-2P2 has a structure that is Formula 1-2b; and when Compound 1-2P1 has a structure that is Formula 1-2b, Compound 1-2P2 has a structure that is Formula 1-2a. The NMR and mass spectra of Compounds 1-2P1 and 1-2P2 are indistinguishable and consistent with a mixture of Compounds 1-2a and 1-2b.

[0193] Example 3: Preparation of Compound 3-2a and Compound 3-2b

[0194] Step 1: Preparation of compounds 3-1a and 3-1b

[0195] A mixture of 1h-2a and 1h-2b (0.052 g, 0.14 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.042 g, 0.42 mmol) and T3P (50% wt in EtOAc, 0.36 g, containing 1-propylphosphonic anhydride, 0.18 g, 0.56 mmol) were added sequentially. A solution of 3-1a-1 (0.041 g, 0.21 mmol) in ethyl acetate (1 mL) was added dropwise. The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain a mixture of 3-1a and 3-1b (0.03 g, 39.21% yield).

[0196] LCMS m / z=547.1[M+H] +

[0197] Step 2: Preparation of Compound 3-2a and Compound 3-2b

[0198] A mixture of 3-1a and 3-1b (0.03 g, 0.027 mmol) was dissolved in dichloromethane (3 mL) and trifluoroacetic acid (0.6 mL) was added dropwise. The mixture was allowed to react at room temperature for 2 h. The reaction mixture was concentrated to obtain a crude product, which was then purified by prep-HPLC (condition 1) to obtain a mixture of 3-2a and compound 3-2b as a trifluoroacetate salt (0.016 g, 58.5% yield).

[0199] LCMS m / z=507.4[M+H] + ;

[0200] Example 4: Preparation of Compound 4-1a and Compound 4-1b

[0201] Step 1: Preparation of compounds 4-1a and 4-1b

[0202] A mixture of 1h-2a and 1h-2b (0.052 g, 0.14 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.042 g, 0.42 mmol) and T3P (50% wt in EtOAc, 0.36 g, containing 1-propylphosphonic anhydride, 0.18 g, 0.56 mmol) were added sequentially. 2C-1 (0.048 g, 0.28 mmol) was then added, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The reaction was quenched with aqueous sodium bicarbonate (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was purified by prep-HPLC (Condition 1) to afford the trifluoroacetic acid salt of a mixture of 4-1a and 4-1b (0.006 g, 8.2% yield).

[0203] LCMS m / z=523.5[M+H] +

[0204] 1H NMR(400MHz,DMSO-d6)δ10.78(d,1H),8.31-8.25(m,1H),7.78-7.72(m,1H),7.69-7.64(m,1H),7.62-7.56(m,1H),7.22-7.13(m,1H ),7.11-7.05(m,1H),4.87(d,1H),4.54-4.45(m,1H),4.01(d,3H),3.27(d,3H),2.68-2.59(m,1H),1.86(s,3H),0.83-0.74(m,3H).

[0205] Example 5: Preparation of Compound 5-3a and Compound 5-3b

[0206] Step 1: Preparation of compounds 5-1a and 5-1b

[0207] A mixture of 1h-2a and 1h-2b (0.022 g, 0.06 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.036 g, 0.36 mmol) and T3P (50% wt in EtOAc, 0.152 g, containing 1-propylphosphonic anhydride, 0.076 g, 0.24 mmol) were added sequentially. Aqueous ammonia (0.008 g, 0.12 mmol) was added, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a mixture of 5-1a and 5-1b.

[0208] LCMS m / z=370.1[M+H] +

[0209] Step 2: Preparation of compounds 5-2a and 5-2b

[0210] Under nitrogen atmosphere and ice bath, a mixture of 5-1a and 5-1b (0.06 mmol) was dissolved in 1,4-dioxane (3 mL). 5-1-1 (0.048 g, 0.09 mmol), Xantphos Pd G2 (CAS: 1375325-77-1) (0.006 g, 0.006 mmol), and cesium carbonate (0.057 g, 0.18 mmol) were added sequentially. The mixture was reacted at 100°C under nitrogen atmosphere for 16 h. The reaction was cooled to room temperature and quenched with water (15 mL). The mixture was extracted with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain a mixture of 5-2a and 5-2b (0.026 g, 52.47% yield).

[0211] Step 3: Preparation of compounds 5-3a and 5-3b

[0212] A mixture of 5-2a and 5-2b (0.026 g, 0.016 mmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (0.6 mL) was added dropwise. The mixture was allowed to react at room temperature for 2 h. Under an ice bath, saturated sodium bicarbonate solution (15 mL) was slowly added dropwise to the reaction system. The mixture was extracted with dichloromethane (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain a mixture of 5-3a and 5-3b (0.012 g, 71.36% yield).

[0213] LCMS m / z=526.0[M+H] + ;

[0214] Example 6: Preparation of Compound 6-2a and Compound 6-2b

[0215] Step 1: Preparation of compounds 6-1a and 6-1b

[0216] A mixture of 1h-2a and 1h-2b (0.049 g, 0.13 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.079 g, 0.78 mmol) and T3P (50% wt in EtOAc, 0.33 g, containing 1-propylphosphonic anhydride, 0.165 g, 0.52 mmol) were added sequentially. 6-1-1 (0.033 g, 0.20 mmol) was then added and allowed to react at room temperature under a nitrogen atmosphere for 18 h. The reaction was quenched by the addition of aqueous sodium bicarbonate (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to afford a mixture of 6-1a and 6-1b (0.056 g, 82.61% yield).

[0217] LCMS m / z=522.2[M+H] +

[0218] Step 2: Preparation of compounds 6-2a and 6-2b

[0219] A mixture of 6-1a and 6-1b (0.056 g, 0.054 mmol) was dissolved in 7 M methanolic ammonia (5 mL) and allowed to react at room temperature for 18 h. The reaction mixture was concentrated to afford a crude product, which was then subjected to prep-HPLC (Condition 1) to afford a mixture of 6-2a and 6-2b (0.036 g, 65.82% yield).

[0220] LCMS m / z=507.2[M+H] + ;

[0221] 1 H NMR(400MHz,DMSO-d6)δ10.52(s,1H),7.87-7.81(m,1H),7.69-7.56(m,3H),7.25-7.13(m ,2H),7.12-7.04(m,1H),4.83(d,1H),4.52-4.45(m,1H),4.00(d,3H),2.66-2.55(m,1H), 1.85(s,3H),0.84-0.72(m,3H).

[0222] Example 7: Preparation of Compound 7-1a and Compound 7-1b

[0223] Preparation of compounds 7-1a and 7-1b

[0224] A mixture of 1h-2a and 1h-2b (0.050 g, 0.14 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.042 g, 0.42 mmol) and T3P (50% wt in EtOAc, 0.35 g, containing 1-propylphosphonic anhydride, 0.175 g, 0.55 mmol) were added sequentially. 7-1-1 (0.033 g, 0.20 mmol) was then added and allowed to react at room temperature under a nitrogen atmosphere for 18 h. The reaction was quenched with aqueous sodium bicarbonate (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was then purified by prep-HPLC (condition 1) and lyophilized to afford a mixture of 7-1a and 7-1b (0.020 g, 27.24% yield).

[0225] LCMS m / z=525.2[M+H] +

[0226] Example 8: Preparation of Compound 8-1a and Compound 8-1b

[0227] Preparation of compounds 8-1a and 8-1b

[0228] A mixture of 1h-2a and 1h-2b (0.050 g, 0.14 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.042 g, 0.42 mmol) and T3P (50% wt in EtOAc, 0.35 g, containing 1-propylphosphoric anhydride, 0.175 g, 0.55 mmol) were added sequentially. 8-1-1 (0.040 g, 0.21 mmol, reference: WO 2020 / 028724) was added, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was then subjected to prep-HPLC (condition 1) and lyophilized to obtain a mixture of 8-1a and 8-1b (0.007 g, 9.22% yield).

[0229] LCMS m / z=543.2[M+H] +

[0230] 1 H NMR(400MHz, CDCl3)δ8.11(s,1H),7.98-7.92(m,1H),7.81-7.76(m,1H),7.17(t,1H),7.05-6.98(m,1H),6.91-6.8 3(m,1H),5.04(s,2H),4.57(d,1H),4.46(dd,1H),4.04(d,3H),2.68-2.59(m,1H),1.92(s,3H),0.91-0.85(m,3H).

[0231] Example 9: Preparation of Compound 9-1a and Compound 9-1b

[0232] A mixture of 1h-1a and 1h-1b (50 mg, 0.14 mmol) was dissolved in DMF (3 mL). 2C-1 (36 mg, 0.21 mmol), TCFH (79 mg, 0.28 mmol), and N-methylimidazole (34 mg, 0.41 mmol) were added sequentially, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compound 9-1a and compound 9-1b (15 mg, 20.95% yield).

[0233] LCMS m / z=523.5[M+H] +

[0234] Example 10: Preparation of Compound 10-1a and Compound 10-1b

[0235] A mixture of 1h-1a and 1h-1b (50 mg, 0.14 mmol) was dissolved in DMF (3 mL). 10-1-1 (40 mg, 0.21 mmol), TCFH (79 mg, 0.28 mmol), and N-methylimidazole (34 mg, 0.42 mmol) were added sequentially, and the mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compounds 10-1a and 10-1b (9.73 mg, 12.86% yield).

[0236] LCMS m / z=541.5[M+H] +

[0237] Example 11: Preparation of Compound 11-1a and Compound 11-1b

[0238] A mixture of 1h-1a and 1h-1b (100 mg, 0.27 mmol) was dissolved in EA (3 mL). 4-Amino-1-methylpyridine-ethanone (40 mg, 0.32 mmol), T3P (50% wt in EtOAc, 680 mg, containing 1-propylphosphonic anhydride, 340 mg, 1.08 mmol), and Et3N (82 mg, 0.81 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added and extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compound 11-1a and compound 11-1b (30 mg, 23.32% yield).

[0239] LCMS m / z=477.1[M+H] +

[0240] Example 12: Preparation of Compound 12-1a and Compound 12-1b

[0241] A mixture of 1h-1a and 1h-1b (100 mg, 0.27 mmol) was dissolved in EA (3 mL). 4-Aminopyridazine (31 mg, 0.33 mmol), T3P (50% wt in EtOAc, 680 mg, containing 1-propylphosphonic anhydride, 340 mg, 1.08 mmol), and Et3N (82 mg, 0.81 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compound 12-1a and compound 12-1b (93.92 mg, 77.75% yield).

[0242] LCMS m / z=448.2[M+H] +

[0243] Example 13: Preparation of Compound 13-1a and Compound 13-1b

[0244] A mixture of 1h-1a and 1h-1b (100 mg, 0.27 mmol) was dissolved in EA (3 mL). 3-Aminopyridine (30 mg, 0.32 mmol), T3P (50% wt in EtOAc, 680 mg, containing 1-propylphosphonic anhydride, 340 mg, 1.08 mmol), and Et3N (82 mg, 0.81 mmol) were added sequentially. The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compounds 13-1a and 13-1b (110 mg, 91.26% yield).

[0245] LCMS m / z=447.1[M+H] +

[0246] Example 14: Preparation of Compound 14-2a and Compound 14-2b

[0247] Step 1: Preparation of Compound 14-1a and Compound 14-1b

[0248] A mixture of 1h-1a and 1h-1b (100 mg, 0.27 mmol) was dissolved in DMF (3 mL). 14-1-1 (prepared according to WO2022121517A1) (91 mg, 0.41 mmol), TCFH (150 mg, 0.53 mmol), and N-methylimidazole (67 mg, 0.82 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (10 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain a mixture of compounds 14-1a and 14-1b (90 mg, 57.81% yield).

[0249] LCMS m / z=577.2[M+H] +

[0250] Step 2: Preparation of Compound 14-2a and Compound 14-2b

[0251] To a mixture of compound 14-1a and compound 14-1b (40 mg, 0.07 mmol) was added a 4M dioxane hydrochloride solution (2 mL). The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The crude product was concentrated and purified via prep-HPLC (condition 1) to afford a mixture of compound 14-2a and compound 14-2b (19.32 mg, 52.19% yield).

[0252] LCMS m / z=537.2[M+H] +

[0253] Example 15: Preparation of Compound 15-2a and Compound 15-2b

[0254] Step 1: Preparation of Compound 15-1a and Compound 15-1b

[0255] A mixture of 1h-1a and 1h-1b (100 mg, 0.27 mmol) was dissolved in EA (3 mL). 5-aminopyridine-2-carbamic acid tert-butyl ester (68 mg, 0.32 mmol), T3P (50% wt in EtOAc, 680 mg containing 1-propylphosphonic anhydride, 340 mg, 1.08 mmol), and Et3N (82 mg, 0.81 mmol) were added sequentially. The mixture was reacted under a nitrogen atmosphere at room temperature for 18 h. Water (5 mL) was added to quench the reaction system and the mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compound 15-1a and compound 15-1b (140 mg, 92.34% yield).

[0256] LCMS m / z=562.2[M+H] +

[0257] Step 2: Preparation of Compound 15-2a and Compound 15-2b

[0258] To a mixture of compound 15-1a and compound 15-1b (100 mg, 0.18 mmol) was added a 4 M dioxane hydrochloride solution (2 mL). The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The crude product was concentrated and purified via prep-HPLC (condition 1) to afford a mixture of compound 15-2a and compound 15-2b (81.11 mg, 97.65% yield).

[0259] LCMS m / z=462.2[M+H] +

[0260] Example 16: Preparation of Compound 16-1a and Compound 16-1b

[0261] A mixture of 1h-1a and 1h-1b (100 mg, 0.27 mmol) was dissolved in EA (3 mL). 5-Aminopyrimidine (31 mg, 0.32 mmol), T3P (680 mg of 50% wt in EtOAc, containing 340 mg of 1-propylphosphonic anhydride, 1.08 mmol), and Et3N (82 mg, 0.81 mmol) were added sequentially. The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (5 mL x 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compounds 16-1a and 16-1b (28.78 mg, 23.82% yield).

[0262] LCMS m / z=448.4[M+H] +

[0263] Example 17: Preparation of Compound 17-1a and Compound 17-1b

[0264] The synthesis method was similar to that of Example 16, and 5-aminopyrimidine was used as the starting material to obtain a mixture of compound 17-1a and compound 17-1b (63.24 mg, yield 52.34%).

[0265] LCMS m / z=448.4[M+H] +

[0266] Example 18: Preparation of Compound 18-2a and Compound 18-2b

[0267] Step 1: Preparation of Compound 18-1a and Compound 18-1b

[0268] The synthesis method was similar to that of Example 16 to obtain a mixture of compound 18-1a and compound 18-1b (40 mg, yield 48.37%).

[0269] LCMS m / z=591.9[M+H] +

[0270] Step 2: Preparation of Compound 18-2a and Compound 18-2b

[0271] To a mixture of compound 18-1a and compound 18-1b (40 mg, 0.068 mmol) was added methanol (1 mL) and hydrochloric acid (0.3 mL). The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The crude product was concentrated and purified by prep-HPLC (condition 1) to afford a mixture of compound 18-2a and compound 18-2b (16 mg, 49.38% yield).

[0272] LCMS m / z=477.1[M+H] +

[0273] Example 19: Preparation of Compound 19-2a and Compound 19-2b

[0274] Step 1: Preparation of Compound 19-1a and Compound 19-1b

[0275] The synthesis method was similar to that of Example 5 to obtain a mixture of compound 19-1a and compound 19-1b (34 mg, yield 52.24%).

[0276] LCMS m / z=592.2[M+H] +

[0277] Step 2: Preparation of Compound 19-2a and Compound 19-2b

[0278] To a mixture of compound 19-1a and compound 19-1b (34 mg, 0.057 mmol) was added methanol (1 mL) and hydrochloric acid (0.3 mL). The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The crude product was concentrated and purified by prep-HPLC (condition 1) to afford a mixture of compound 19-2a and compound 19-2b (20 mg, 73.49% yield).

[0279] LCMS m / z=478.50[M+H] +

[0280] Example 20: Preparation of Compound 20-1a and Compound 20-1b

[0281] The synthesis method was similar to that of Example 16 to obtain a mixture of compound 20-1a and compound 20-1b (3 mg, yield 4.63%).

[0282] LCMS m / z=463.1[M+H] +

[0283] Example 21: Preparation of Compound 21-1a and Compound 21-1b

[0284] Step 1: Preparation of compounds 1e-2a and 1e-2b

[0285] 1e (51.0 g, 126.86 mmol) was purified by column chromatography to give a mixture of 1e-2a and 1e-2b (17.6 g, 34% yield).

[0286] Step 2: Preparation of compound 21-2

[0287] Compound 21-1 (350 mg, 1.63 mmol) (prepared according to WO 2021093820 Al), (Bpin)2 (496 mg, 1.96 mmol), potassium acetate (480 mg, 4.89 mmol), and Pd(dppf)Cl2·DCM (119 mg, 0.16 mmol) were added to 1,4-dioxane (10 mL) and reacted at 100°C under nitrogen for 5 h. The reaction solution was used directly in the next step.

[0288] Step 3: Preparation of compounds 21-3a and 21-3b

[0289] To the previous reaction mixture, 1e-2a and 1e-2b (655 mg, 1.63 mmol), Pd(PPh3)4 (94 mg, 0.08 mmol), potassium phosphate (1.04 g, 4.90 mmol), and water (0.5 mL) were added. The mixture was reacted at 100°C under a nitrogen atmosphere for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The mixture was then purified on a silica gel column to afford a mixture of 21-3a and 21-3b (420 mg, 66.34% yield).

[0290] LCMS m / z=389.2[M+H] +

[0291] Step 4: Preparation of 21-4a and 21-4b

[0292] A mixture of 21-3a and 21-3b (220 mg, 0.57 mmol) was dissolved in methanol (8 mL), and platinum oxide (52 mg) was added. The mixture was reacted at room temperature under a hydrogen atmosphere for 18 h. The mixture was filtered through celite, and the filtrate was concentrated and purified on a silica gel column to obtain a mixture of 21-4a and 21-4b (88 mg, 39.54% yield).

[0293] Step 5: Preparation of 21-5a and 21-5b

[0294] A mixture of 21-4a and 21-4b (50 mg, 0.13 mmol) was dissolved in anhydrous ethanol (3 mL), and cesium carbonate (64 mg, 0.2 mmol) was added. The mixture was reacted at 50°C for 3 h. The reaction solution was cooled to room temperature and quenched by adding 1M hydrochloric acid (5 mL). The mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography to obtain a mixture of 21-5a and 21-5b (40 mg, 84.91% yield).

[0295] LCMS m / z=361.1[MH] -

[0296] Step 6: Preparation of 21-6a and 21-6b

[0297] A mixture of 21-5a and 21-5b (40 mg, 0.11 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (33 mg, 0.33 mmol), T3P (50% wt in EtOAc, 280 mg, containing 1-propylphosphonic anhydride, 140 mg, 0.44 mmol), and methyl 4-aminopyridine-2-carboxylate (40 mg, 0.11 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was then purified on a silica gel column to afford a mixture of 21-6a and 21-6b (8 mg, 14.65% yield).

[0298] LCMS m / z=497.6[M+H] +

[0299] Step 7: Preparation of Compound 21-7a and Compound 21-7b

[0300] A mixture of 21-6a and 21-6b (8 mg, 0.039 mmol) was dissolved in 7M methanolic ammonia solution (1 mL) and allowed to react at room temperature for 18 h. The reaction system was concentrated to obtain a crude product, which was purified by silica gel column chromatography to afford a mixture of compounds 21-7a and 21-7b (1 mg, 13.01% yield).

[0301] LCMS m / z=482.2[M+H] +

[0302] Using 110 mg of a mixture of compound 21-7a and compound 21-7b as starting material, chiral separation was performed to obtain compound 21-7P1 (38.3 mg, retention time: 1.576 min) and compound 21-7P2 (38 mg, retention time: 1.723 min).

[0303] Compound 21-7P1 is one of the above 21-7a and 21-7b; and is an enantiomer of compound 21-7P2, that is, when the structure of compound 21-7P1 is the structure of formula 21-7a, the structure of compound 21-7P2 is the structure of formula 21-7b; when the structure of compound 21-7P1 is the structure of formula 21-7b, the structure of compound 21-7P2 is the structure of formula 21-7a.

[0304] SFC preparation conditions:

[0305] Instrument: Waters 150 Prep-SFC C, preparative column: Chiral IC column. Preparation: Dissolve the crude product in acetonitrile to a 10 mg / mL sample solution. Mobile phase: CO2 / 0.1% NH3·H2O methanol solution, methanol content 15%; elution time: 15 min.

[0306] Chiral test method: (Instrument: SHIMADZU LC-30 AD sf, Preparative column: Chiral IC column. Preparation method: Dissolve the crude product in acetonitrile to prepare the sample solution. Mobile phase system: carbon dioxide / 0.05% DEA in methanol solution. Elution gradient: 5%-40%; flow rate: 3.0 mL / min, elution time: 3 min).

[0307] Example 22: Preparation of Compound 22-1a and Compound 22-1b

[0308] A mixture of 1h-2a and 1h-2b (50 mg, 0.135 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (42 mg, 0.42 mmol) and T3P (50% wt in EtOAc, 350 mg containing 1-propylphosphonic anhydride, 175 mg, 0.55 mmol) were added sequentially. Then, 22-1a-1 (34 mg, 0.20 mmol) was added and allowed to react at room temperature under a nitrogen atmosphere for 18 h. The reaction was quenched by the addition of aqueous sodium bicarbonate (10 mL) and extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to afford a mixture of 22-1a and 22-1b (42 mg, 59% yield).

[0309] LCMS m / z=524.0[M+H] + ;

[0310] 1H NMR(400MHz, CDCl3)δ8.44(s,1H),8.02(d,1H),7.95(t,1H),7.67(d,1H),7.52(t,1H),7.04-6.95(m,1H),6.89-6.80 (m,1H),4.63(d,1H),4.56-4.45(m,1H),4.05(t,3H),3.10(s,3H),2.72-2.56(m,1H),1.93(s,3H),0.94-0.80(m,3H).

[0311] Example 23: Preparation of Compounds 23-8a and 23-8b

[0312] Step 1: Preparation of compound 23-2

[0313] 23-1 (7.9 g, 50.0 mmol), vinylboronic acid pinacol ester (8.47 g, 55.0 mmol), potassium carbonate (13.8 g, 100.0 mmol), and Pd(dppf)Cl2·DCM (0.51 g, 0.75 mmol) were added to a mixed solvent of 1,4-dioxane (120 mL) and water (30 mL) and reacted at 100°C under a nitrogen atmosphere for 4 h. The reaction solution was cooled to room temperature, ethyl acetate (200 mL) was added, and the mixture was washed with saturated brine (50 mL × 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by column chromatography to obtain 23-2 (4.6 g, 61% yield).

[0314] LCMS m / z=151.0[M+H] +

[0315] Step 2: Preparation of compound 23-3

[0316] 23-2 (4.6 g, 30.66 mmol), silver benzoate (21.0 g, 91.98 mmol), and iodine (12.4 g, 49.05 mmol) were added to toluene (150 mL) and refluxed under a nitrogen atmosphere for 20 h. The reaction solution was cooled to room temperature and filtered through celite. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford 23-3 (5.88 g, 49% yield).

[0317] LCMS m / z=393.1[M+H] +

[0318] Step 3: Preparation of compound 23-4

[0319] Compound 23-3 (5.88 g, 15.0 mmol) and lithium hydroxide monohydrate (2.52 g, 60.0 mmol) were added to a mixture of tetrahydrofuran (80 mL) and water (20 mL) and allowed to react at room temperature for 3 h. The reaction solution was extracted with ethyl acetate (300 mL), and the organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified on a silica gel column to afford compound 23-4 (117 mg, 4% yield).

[0320] LCMS m / z=185.1[M+H] +

[0321] Step 4: Preparation of compound 23-5

[0322] Compound 23-4 (117 mg, 0.635 mmol), 2,2-dimethoxypropane (198 mg, 1.9 mmol), and p-toluenesulfonic acid monohydrate (18 mg, 0.095 mmol) were added to tetrahydrofuran (5 mL) and reacted at room temperature for 4 h. The reaction solution was concentrated under reduced pressure and purified on a silica gel column to afford compound 23-5 (110 mg, 76% yield).

[0323] Step 5: Preparation of compound 23-6

[0324] 23-5 (110 mg, 0.486 mmol) and palladium on carbon (10%) (22 mg) were added to ethyl acetate (3 mL) and ethanol (3 mL) and reacted at room temperature under a hydrogen atmosphere for 16 h. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure and purified on a silica gel column to afford 23-6 (89 mg, 94% yield).

[0325] LCMS m / z=195.1[M+H] +

[0326] Step 6: Preparation of 23-7a and 23-7b

[0327] A mixture of 1h-2a and 1h-2b (50 mg, 0.135 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (42 mg, 0.42 mmol), T3P (50% wt in EtOAc, 350 mg containing 1-propylphosphonic anhydride, 175 mg, 0.55 mmol), and 23-6 (40 mg, 0.20 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was then purified on a silica gel column to afford a mixture of 23-7a and 23-7b (68 mg, 92% yield).

[0328] LCMS m / z=547.1[M+H] +

[0329] Step 7: Preparation of Compound 23-8a and Compound 23-8b

[0330] A mixture of compounds 23-7a and 23-7b (68 mg, 0.124 mmol) was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (1 mL) was added. The mixture was allowed to react at room temperature for 1 h. The reaction solution was concentrated under reduced pressure and then subjected to Prep-HPLC (Condition 1) to obtain the trifluoroacetate salt of the mixture of compounds 23-8a and 23-8b (40 mg, 52% yield).

[0331] LCMS m / z=507.1[M+H] + ;

[0332] Example 24: Preparation of Compounds 24-9a and 24-9b

[0333] Step 1: Preparation of compound 24-2

[0334] 24-1 (4.0 g, 15.6 mmol), 3-bromo-2-methylpropene (2.53 g, 18.74 mmol), and potassium carbonate (4.3 g, 31.2 mmol) were added to acetonitrile (60 mL) and reacted at 60°C under a nitrogen atmosphere for 12 h. The reaction solution was cooled to room temperature and filtered through celite. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford 24-2 (4.8 g, 99% yield).

[0335] Step 2: Preparation of compound 24-3

[0336] 24-2 (4.8 g, 15.4 mmol) was added to dichloromethane (150 mL) and placed in an ice bath. Aluminum chloride (107 mg, 0.8 mmol) was added and the reaction continued in the ice bath for 1 h. The reaction solution was quenched by adding icy sodium bicarbonate aqueous solution and extracted with ethyl acetate (200 mL). The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified on a silica gel column to obtain 24-3 (4.0 g, 83% yield).

[0337] Step 3: Preparation of compound 24-4

[0338] 24-3 (2.02 g, 6.51 mmol), (Bpin)2 (CAS: 73183-34-3) (2.15 g, 8.46 mmol), potassium acetate (1.28 g, 13.0 mmol), and Pd(dppf)Cl2·DCM (265 mg, 0.32 mmol) were added to 1,4-dioxane (40 mL) and reacted at 100°C under a nitrogen atmosphere for 5 h. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and purified by silica gel column chromatography to afford 24-4 (660 mg, 30% yield).

[0339] Step 4: Preparation of compounds 24-5a and 24-5b

[0340] 24-4 (286 mg, 0.8 mmol), 1e-2a and 1e-2b (300 mg, 0.746 mmol), Pd(PPh3)4 (43 mg, 0.04 mmol), and potassium phosphate (474 ​​mg, 2.4 mmol) were added to toluene (9 mL) and water (3 mL) and reacted at 100°C under a nitrogen atmosphere for 16 h. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The mixture was purified by silica gel column chromatography to obtain a mixture of 24-5a and 24-5b (300 mg, 77% yield).

[0341] Step 5: Preparation of 24-6a and 24-6b

[0342] A mixture of 24-5a and 24-5b (300 mg, 0.62 mmol) was dissolved in methanol (30 mL), and palladium on carbon (10%) (100 mg) was added. The mixture was reacted at 90°C under a hydrogen atmosphere at 2.5 MPa for 70 h. The reaction solution was cooled to room temperature, filtered through celite, and the filtrate was concentrated and purified on a silica gel column to obtain a mixture of 24-6a and 24-6b (180 mg, 60% yield).

[0343] Step 6: Preparation of 24-7a and 24-7b

[0344] A mixture of 24-6a and 24-6b (130 mg, 0.267 mmol) was dissolved in anhydrous ethanol (5 mL), and cesium carbonate (160 mg, 0.4 mmol) was added. The mixture was reacted at 50°C for 3 h. The reaction solution was cooled to room temperature and quenched by adding 1M hydrochloric acid (5 mL). The mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography to obtain a mixture of 24-7a and 24-7b (120 mg, 98% yield).

[0345] LCMS m / z=457.0[MH] -

[0346] Step 7: Preparation of 24-8a and 24-8b

[0347] A mixture of 24-7a and 24-7b (46 mg, 0.1 mmol) was dissolved in ethyl acetate (2 mL). Triethylamine (42 mg, 0.42 mmol), T3P (50% wt in EtOAc, 350 mg, containing 1-propylphosphonic anhydride, 175 mg, 0.55 mmol), and 1h-2 (40 mg, 0.20 mmol) were added sequentially. The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was then purified on a silica gel column to afford a mixture of 24-8a and 24-8b (23 mg, 39% yield).

[0348] LCMS m / z=593.1[M+H] +

[0349] Step 8: Preparation of Compound 24-9a and Compound 24-9b

[0350] A mixture of 24-8a and 24-8b (23 mg, 0.039 mmol) was dissolved in 7 M methanolic ammonia solution (3 mL) and allowed to react at room temperature for 18 h. The reaction system was concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a mixture of compound 24-9a and compound 24-9b (14 mg, 62% yield).

[0351] LCMS m / z=578.1[M+H] +

[0352] 1 H NMR(400MHz, CDCl3)δ9.82(s,1H),8.46(d,1H),8.39-8.27(m,1H),8.16(d,1H),8.00(d,1H),7.06(d,1H),6.68(d,1H),5.88(d, 1H),5.09(d,1H),4.43-4.29(m,1H),3.02(s,2H),2.83-2.70(m,1H),1.90(s,3H),1.48(s,3H),1.42(s,3H),1.00-0.90(m,3H).

[0353] Example 25: Preparation of Compound 25-1a and Compound 25-1b

[0354] A mixture of compounds 1h-1a and 1h-1b (50 mg, 0.14 mmol) was dissolved in EA (1.5 mL). 2-(Methylsulfonyl)pyridin-4-amine (45 mg, 0.26 mmol), T3P (50% wt in EtOAc, 340 mg containing 1-propylphosphonic anhydride, 170 mg, 0.54 mmol), and Et3N (82 mg, 0.81 mmol) were added sequentially. The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compounds 25-1a and 25-1b (7.23 mg, 18.62% yield).

[0355] LCMS m / z=525.60[M+H] +

[0356] Example 26: Preparation of Compound 26-1a and Compound 26-1b

[0357] A mixture of compounds 1h-1a and 1h-1b (50 mg, 0.13 mmol) was dissolved in ethyl acetate (1.5 mL). 4-Fluoro-3-(methylsulfonyl)aniline (51 mg, 0.26 mmol), T3P (50% wt in EtOAc, 340 mg, containing 1-propylphosphonic anhydride, 170 mg, 0.54 mmol), and Et3N (82 mg, 0.81 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Water (5 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with saturated brine (5 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain a mixture of compounds 26-1a and 26-1b (37.21 mg, 33.95% yield).

[0358] LCMS m / z=542.60[M+H] +

[0359] 1H NMR(400MHz, CDCl3)δ8.84(s,1H),8.42-8.30(m,1H),7.82-7.73(m,1H),7.21(t,1H),6.99-6.90(m,1H),6.87-6.76( m,1H),4.70(d,1H),4.61-4.52(m,1H),4.05(d,3H),3.34(s,3H),2.67-2.58(m,1H),1.92(s,3H),0.95-0.85(m,3H).

[0360] Example 27: Preparation of Compound 27-1a and Compound 27-1b

[0361] A mixture of 1h-2a and 1h-2b (0.052 g, 0.14 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.085 g, 0.84 mmol) and T3P (50% wt in EtOAc, 0.36 g, containing 1-propylphosphonic anhydride, 0.18 g, 0.56 mmol) were added sequentially. 27-1a-1 (0.040 g, 0.21 mmol) was added to the system, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) to obtain the trifluoroacetic acid salt of the mixture of 27-1a and 27-1b.

[0362] LCMS m / z=541.1[M+H] +

[0363] 1 H NMR(400MHz,DMSO-d6)δ10.72(s,1H),8.17-8.09(m,1H),7.81-7.72(m,1H),7.37(t,1H),7.22-7.14(m,1H),7.11-7.0 4(m,1H),4.83(d,1H),4.53-4.45(m,1H),4.00(d,3H),3.19(s,3H),2.65-2.57(m,1H),1.85(s,3H),0.83-0.74(m,3H).

[0364] Example 28: Preparation of Compound 28-2a and Compound 28-2b

[0365] Step 1: Preparation of compounds 28-1a and 28-1b

[0366] A mixture of 1h-2a and 1h-2b (0.052 g, 0.14 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.085 g, 0.84 mmol) and T3P (50% wt in EtOAc, 0.36 g, containing 1-propylphosphonic anhydride, 0.18 g, 0.56 mmol) were added sequentially. 28-1a-1 (0.032 g, 0.21 mmol) was then added, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The reaction was quenched by the addition of aqueous sodium bicarbonate (10 mL). The mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to afford a mixture of 28-1a and 28-1b (0.06 g, 85.12% yield).

[0367] LCMS m / z=504.1[M+H] +

[0368] Step 2: Preparation of compounds 28-2a and 28-2b

[0369] A mixture of 28-1a and 28-1b (0.06 g, 0.12 mmol) was dissolved in 7 M methanolic ammonia (5 mL) and heated to 40°C in a sealed tube for 18 h. The reaction mixture was concentrated to obtain a crude product, which was purified by silica gel column chromatography to afford a mixture of 28-2a and 28-2b (0.02 g, 34.12% yield).

[0370] LCMS m / z=489.3[M+H] + ;

[0371] 1 H NMR(400MHz,DMSO-d6)δ10.46(s,1H),7.99(t,1H),7.90(s,1H),7.66-7.61(m,1H),7.56-7.51(m,1H),7.39-7.27(m,2 H),7.23-7.06(m,2H),4.87(d,1H),4.53-4.45(m,1H),4.00(d,3H),2.65-2.56(m,1H),1.86(s,3H),0.82-0.75(m,3H).

[0372] Example 29: Preparation of Compound 29-1a and Compound 29-1b

[0373] Step 1: Preparation of compound 29b

[0374] 29a (3.28 g, 15.0 mmol) was dissolved in methanol (50 mL), and triethylamine (1.52 g, 14.99 mmol) and (Boc)2O (6.48 g, 29.98 mmol) were added sequentially. The mixture was reacted at 50°C for 18 h. The reaction mixture was concentrated to obtain a crude product, which was purified by silica gel column chromatography to afford 29b (4.47 g, 93.38% yield).

[0375] LCMS m / z=264.0[M-55] +

[0376] Step 2: Preparation of compound 29c

[0377] 29b (4.46 g, 13.96 mmol) was dissolved in DMSO (50 mL), and 29b-1 (7.08 g, 34.90 mmol) and copper powder (2.22 g, 34.90 mmol) were added sequentially. The reaction was allowed to react at 80°C under a nitrogen atmosphere for 18 h. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with ethyl acetate (10 mL × 3). The filtrate was quenched with water (500 mL) and extracted with ethyl acetate (50 mL × 3). The organic phases were combined and washed with saturated sodium chloride solution (200 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford 29c (3.3 g, 74.97% yield).

[0378] Step 3: Preparation of compound 29d

[0379] 29c (0.50 g, 1.6 mmol) was dissolved in ethyl acetate (10 mL), and p-toluenesulfonic acid (0.69 g, 4.0 mmol) was added. The reaction was allowed to react at 45°C under a nitrogen atmosphere for 18 h. The reaction system was concentrated to obtain a crude product, which was dissolved in water (10 mL). Saturated sodium carbonate solution was slowly added dropwise under an ice bath until the pH reached 9-10. The product was extracted with dichloromethane:methanol (10:1) (15 mL x 4). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 29d (0.32 g, 92.94% yield).

[0380] LCMS m / z=216.1[M+1] +

[0381] Step 4: Preparation of compounds 29e-1a and 29e-1b

[0382] A mixture of 1h-2a and 1h-2b (0.052 g, 0.14 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.085 g, 0.84 mmol) and T3P (50% wt in EtOAc, 0.36 g, containing 1-propylphosphonic anhydride, 0.18 g, 0.56 mmol) were added sequentially. 29d (0.045 g, 0.21 mmol) was then added, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The reaction was quenched with aqueous sodium bicarbonate (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to afford a mixture of 29e-1a and 29e-1b (0.048 g, 60.41% yield).

[0383] Step 5: Preparation of compounds 29-1a and 29-1b

[0384] A mixture of 29e-1a and 29e-1b (0.048 g, 0.084 mmol) was dissolved in methanol (3 mL) and ice-cooled for 10 minutes. Sodium borohydride (0.0032 g, 0.084 mmol) was added and the mixture was allowed to react in an ice-cooled bath for 2 hours. Water (10 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous sulfuric acid, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain a mixture of 29-1a and 29-1b (0.02 g, 45.31% yield).

[0385] LCMS m / z=524.1[M+H] - ;

[0386] 1 H NMR(400MHz,DMSO-d6)δ10.52(s,1H),7.60(d,2H),7.43(d,2H),7.22-7.13(m,1H),7.11-7.05(m,1H),5.52(t,1H), 4.87(d,1H),4.52-4.44(m,1H),3.99(d,3H),3.84-3.73(m,2H),2.65-2.57(m,1H),1.85(s,3H),0.82-0.74(m,3H).

[0387] Example 30: Preparation of Compound 30

[0388] Step 1: Preparation of compound 30b

[0389] Under ice-cooling, 30a (0.88 g, 6.28 mmol) was dissolved in tetrahydrofuran (15 mL), and LiHMDS (2.53 g, 13.82 mmol) was added dropwise. Di-tert-butyl dicarbonate (1.51 g, 6.91 mmol) was dissolved in tetrahydrofuran (5 mL) and slowly added dropwise. The mixture was allowed to warm to room temperature under a nitrogen atmosphere for 18 h. Under ice-cooling, the reaction was quenched with saturated aqueous ammonium chloride (30 mL). The mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford 30b (1.4 g, 92.76% yield).

[0390] Step 2: Preparation of compound 30c

[0391] 30b (1.41 g, 5.87 mmol) was dissolved in methanol (10 mL), and ammonium carbamate (1.83 g, 23.48 mmol) and iodobenzene acetate (5.67 g, 17.61 mmol) were added sequentially. The mixture was allowed to react at room temperature for 18 h. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography to afford 30c (1.14 g, 71.57% yield).

[0392] Step 3: Preparation of compound 30d

[0393] 30c (0.054 g, 0.2 mmol) was dissolved in dichloromethane (2.5 mL), trifluoroacetic acid (0.5 mL) was added, and the mixture was reacted at room temperature for 2 h. The solvent was removed by concentration under reduced pressure to obtain crude product 30d.

[0394] LCMS m / z=172.1[M+1] +

[0395] Step 4: Preparation of compound 30

[0396] 1h-2a (0.037 g, 0.1 mmol) was dissolved in ethyl acetate (3 mL). Triethylamine (0.061 g, 0.60 mmol) and T3P (50% wt in EtOAc, 0.25 g, containing 1-propylphosphonic anhydride, 0.125 g, 0.40 mmol) were added sequentially. 30d (0.026 g, 0.15 mmol) was then added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC (condition 1) and lyophilized to afford compound 30 (0.003 g, 5.73% yield).

[0397] LCMS m / z=524.1[M+H] + ;

[0398] Example 31: Preparation of Compound 31-1a and Compound 31-1b

[0399] Step 1: Preparation of compound 31b

[0400] 31a-1 (29.14 g, 130 mmol) was dissolved in tetrahydrofuran (100 mL) under an ice bath. Sodium hydride (5.2 g, 130 mmol) was added portionwise. The mixture reacted under a nitrogen atmosphere and ice bath for 30 minutes. A solution of 1a (11.20 g, 100 mmol) in tetrahydrofuran (20 mL) was then added dropwise. The mixture was allowed to warm to room temperature under a nitrogen atmosphere and reacted for 18 hours. Under an ice bath, 1N hydrochloric acid was slowly added dropwise to the reaction system until the pH reached 7-8. The mixture was extracted with diethyl ether (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated (at room temperature) to afford the crude product. The crude product was purified by silica gel column chromatography to afford 31b (9.5 g, 52.16% yield).

[0401] Step 2: Preparation of compound 31c

[0402] Under ice-cooling, 31b (4.8 g, 26.37 mmol) was added to a round-bottom flask. Piperidine (0.45 g, 5.27 mmol) was added dropwise to the system, followed by 31b-1 (2.80 g, 26.37 mmol). The reaction was allowed to react at 30°C under nitrogen for 48 h. Under ice-cooling, the reaction system was quenched by the addition of 0.1N hydrochloric acid (50 mL). The mixture was extracted with diethyl ether (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated (25°C) to afford the crude product. This crude product was purified by silica gel column chromatography to afford 31c (2.57 g, 33.81% yield).

[0403] LCMS m / z=289.1[M+H] +

[0404] Step 3: Preparation of compound 31d

[0405] Under a nitrogen atmosphere, 31c (2.57 g, 8.91 mmol) was dissolved in diethyl ether (30 mL) and precooled in an ice bath for 10 min. A 1 M solution of potassium tert-butoxide in tetrahydrofuran (1.43 mL) was slowly added dropwise, and the reaction was continued in an ice bath for 2 h. In an ice bath, glacial acetic acid (0.7 mL) and water (30 mL) were slowly added dropwise to quench the reaction. The mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined and washed with saturated aqueous sodium bicarbonate (100 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and concentrated to yield crude product 31d.

[0406] Step 4: Preparation of compound 31e

[0407] 31d (1.97 g, 8.13 mmol) was dissolved in dry dichloromethane (20 mL) and precooled at -78°C for 15 minutes. N,N-diisopropylethylamine (1.26 g, 9.76 mmol) was added dropwise under a nitrogen atmosphere, followed by a solution of trifluoromethanesulfonic anhydride (2.29 g, 8.13 mmol) in dichloromethane (5 mL). The reaction was allowed to react at -78°C for 2 hours. Under an ice bath, saturated aqueous sodium bicarbonate (30 mL) was slowly added to the reaction system to quench the reaction. The mixture was extracted with dichloromethane (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford 31e (0.680 g, 22.35% yield).

[0408] Step 5: Preparation of compound 31f

[0409] 31e (0.68 g, 1.82 mmol) was dissolved in toluene (15 mL). 1e-1 (0.38 g, 2.00 mmol) and tetrakis(triphenylphosphine)palladium (0.11 g, 0.091 mmol) were added sequentially. Potassium phosphate (1.16 g, 5.46 mmol) was prepared into a 2M aqueous solution and added to the system. After addition, the reaction was incubated at 100°C under a nitrogen atmosphere for 3 h. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with ethyl acetate (10 mL × 2). The filtrate was separated and the organic phase was collected. The aqueous phase was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain 31f (0.66 g, 98.46% yield).

[0410] Step 6: Preparation of compound 31g

[0411] 31f (0.55 g, 1.49 mmol) was dissolved in ethanol (15 mL), and platinum dioxide (0.12 g, 0.51 mmol) was added. The reaction was incubated at 25°C under a hydrogen atmosphere for 18 h. The reaction mixture was filtered, and the filter cake was washed with ethyl acetate (5 mL x 2). The filtrate was collected and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford 31 g (0.53 g, 96.05% yield).

[0412] Step 7: Preparation of compound 31h

[0413] 31g (0.53g, 1.43mmol) was dissolved in ethanol (15mL), cesium carbonate (0.70g, 2.15mmol) was added, and the mixture was reacted at 50°C for 2h. The reaction system was concentrated to obtain a crude product, which was dissolved in water (15mL), adjusted to pH 1-2 with 1N hydrochloric acid, and extracted with ethyl acetate (20mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product 31h.

[0414] LCMS m / z=355.3[MH] -

[0415] Step 8: Preparation of compounds 31i-1a and 31i-1b

[0416] 31h (0.51 g, 1.43 mmol) was dissolved in ethyl acetate (15 mL), and triethylamine (0.87 g, 8.59 mmol) and T3P (3.64 g of 50% wt in EtOAc, containing 1.82 g, 5.72 mmol of 1-propylphosphoric anhydride) were added sequentially. 1h-2 (0.33 g, 2.15 mmol) was added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (15 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford a mixture of 31i-1a and 31i-1b (0.34 g, 48.43% yield).

[0417] LCMS m / z=491.1[M+H] +

[0418] Step 9: Preparation of Compound 31-1a and Compound 31-1b

[0419] A mixture of compounds 31i-1a and 31i-1b (0.34 g, 0.70 mmol) was dissolved in 7 M methanolic ammonia (10 mL) and allowed to react at room temperature for 18 h. The reaction mixture was concentrated to afford the crude product, which was then purified by prep-HPLC (neutral preparation) and lyophilized to afford a mixture of compounds 31-1a and 31-1b (0.21 g, 63.10% yield).

[0420] LCMS m / z=476.1[M+H] + ;

[0421] 1 H NMR (400MHz, CDCl3): δ9.84(s,1H),8.45(d,1H),8.36-8.29(m,1H),8.13(d,1H),8.08-7.96(m,1H),7.05-6.96(m,1H),6.89 -6.78(m,1H),6.07-5.95(m,1H),4.74(d,1H),4.38-4.25(m,1H),4.06(d,3H),2.60(t,1H),2.33-2.22(m,1H),1.79(s,3H).

[0422] A mixture of compounds 31-1a and 31-1b (0.21 g) was prepared by SFC and lyophilized to give compounds 31-1P1 (86.0 mg, retention time: 5.345 min) and 31-1P2 (90.0 mg, retention time: 7.364 min). Chiral analysis method: (Instrument: Shimadzu LC-20AT, Chiral column: Daicel AD-H. Preparation method: The crude product was dissolved in acetonitrile to prepare a sample solution. Mobile phase system: n-hexane / ethanol, ethanol content 20%; flow rate: 1.0 mL / min, elution time: 30 min).

[0423] SFC preparation conditions:

[0424] Instrumentation: SFC Prep 150 AP, Preparative Column: Daicel IC-H (19 mm × 250 mm). Preparation: Dissolve the crude product in methanol and filter through a 0.45 μm filter to prepare the sample solution. Mobile phase: CO2 / methanol:isopropanol (1:1), methanol:isopropanol (1:1) (18%); Flow rate: 35 mL / min.

[0425] The structure of compound 31-1P1 is one of the above formulas 31-1a and 31-1b; and it is an enantiomer of compound 31-1P2, that is, when the structure of compound 31-1P1 is the structure of formula 31-1a, the structure of compound 31-1P2 is the structure of formula 31-1b; when the structure of compound 31-1P1 is the structure of formula 31-1b, the structure of compound 31-1P2 is the structure of formula 31-1a.

[0426] Example 32: Preparation of Compound 32-1a and Compound 32-1b

[0427] A mixture of 31h (0.18 g, 0.5 mmol) was dissolved in ethyl acetate (15 mL). Triethylamine (0.30 g, 3 mmol) and T3P (50% wt in EtOAc, 1.28 g, containing 0.64 g, 2 mmol, of 1-propylphosphoric anhydride) were added sequentially. 32a-1 (0.10 g, 0.75 mmol) was then added, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (15 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain 120 mg of a mixture of compounds 32-1a and 32-1b.

[0428] LCMS m / z=475.1[M+H] +

[0429] 1H NMR (400MHz, CDCl3): δ8.46(s,1H),7.99-7.94(m,1H),7.93-7.87(m,1H),7.51-7.45(m,1H),7.38(t,1H),7.04-6.96(m,1H),6 .90-6.80(m,1H),6.36-5.53(m,2H),4.52(d,1H),4.27-4.14(m,1H),4.00(d,3H),2.59(t,1H),2.29-2.20(m,1H),1.81(s,3H).

[0430] A mixture of 120.0 mg of compounds 32-1a and 32-1b was prepared by SFC and lyophilized to give compounds 32-1P1 (48.0 mg, retention time: 5.732 min) and 32-1P2 (50.0 mg, retention time: 5.168 min). Chiral analysis method: (Instrument: Shimadzu LC-20AT, Chiral column: Daicel AD-H. Preparation method: Dissolve the crude product in acetonitrile to prepare a sample solution. Mobile phase: n-hexane / ethanol, 20% ethanol content; flow rate: 1.0 mL / min, elution time: 30 min).

[0431] SFC preparation conditions:

[0432] Instrument: SFC Prep 150 AP, Preparative Column: Daicel IC-H (19 mm × 250 mm). Preparation: Dissolve the crude product in methanol and filter through a 0.45 μm filter to prepare the sample solution. Mobile phase: CO2 / methanol:isopropanol (9:1), methanol:isopropanol (9:1) at 20% concentration; Flow rate: 40 mL / min.

[0433] The structure of compound 32-1P1 is one of the above formulas 32-1a and 32-1b; and it is an enantiomer of compound 32-1P2, that is, when the structure of compound 32-1P1 is the structure of formula 32-1a, the structure of compound 32-1P2 is the structure of formula 32-1b; when the structure of compound 32-1P1 is the structure of formula 32-1b, the structure of compound 32-1P2 is the structure of formula 32-1a.

[0434] Example 33: Preparation of Compound 33-1a and Compound 33-1b

[0435] Step 1: Preparation of Compound 33-1a and Compound 33-1b

[0436] A mixture of 1h-2a and 1h-2b (0.05 g, 0.13 mmol) was dissolved in oxalyl chloride (1 mL). DMF (0.002 g, 0.028 mmol) was added dropwise under an ice bath and allowed to react at room temperature for 2 h. After concentration, the crude product was added to a solution of 33-1a-1 (prepared according to WO2022121517A1) (0.044 g, 0.20 mmol) and triethylamine (0.039 g, 0.39 mmol) in dichloromethane (1 mL) and allowed to react overnight at room temperature. The crude product was concentrated to afford the crude product, which was then purified by silica gel column chromatography to afford a mixture of 33a-1a and 33a-1b (0.036 g, 48.03% yield).

[0437] Step 2: Preparation of Compound 33-1a and Compound 33-1b

[0438] To a mixture of 33a-1a and 33a-1b (0.036 g, 0.062 mmol), dioxane hydrochloride solution (4 M, 1 mL) was added and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The crude product was concentrated and purified by prep-HPLC (condition 1) to afford a mixture of compounds 33-1a and 33-1b (0.01 g, 30.06% yield).

[0439] LCMS m / z=537.5[M+H] +

[0440] Example 34: Preparation of Compound 34-1a and Compound 34-1b

[0441] Step 1: Preparation of compound 34a

[0442] 1e (0.5 g, 1.29 mmol) was dissolved in toluene (5 mL), and 34-1a-1 (0.24 g, 1.42 mmol) and Pd(PPh3)4 (0.075 g, 0.065 mmol) were added sequentially. Potassium phosphate (0.82 g, 3.87 mmol) was prepared into a 2 M aqueous solution and added to the system. The reaction was incubated at 100°C under a nitrogen atmosphere for 6 h. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with ethyl acetate (10 mL × 2). The filtrate was separated and the organic phase was collected. The aqueous phase was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain 34a (0.45 g, 91.72% yield).

[0443] Step 2: Preparation of compounds 34b-1a and 34b-1b

[0444] 34a (0.45 g, 1.24 mmol) was dissolved in methanol (5 mL), and palladium on carbon (0.3 g, 0.29 mmol) was added. The mixture was reacted at 90°C under a hydrogen atmosphere, pressurized to 2.5 MPa, for 72 h. The reaction mixture was filtered and the filtrate was concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford a mixture of 34b-1a and 34b-1b (0.26 g, 57.55% yield).

[0445] Step 3: Preparation of compounds 34c-1a and 34c-1b

[0446] A mixture of 34b-1a and 34b-1b (0.25 g, 0.69 mmol) was dissolved in ethanol (3 mL), and cesium carbonate (0.34 g, 1.03 mmol) was added. The mixture was reacted at 50°C for 4 h. 1N hydrochloric acid was slowly added dropwise to the system under ice until the pH reached 1. Water (5 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude mixture of 34c-1a and 34c-1b.

[0447] Step 4: Preparation of compounds 34d-1a and 34d-1b

[0448] A mixture of 34c-1a and 34c-1b (0.1 g, 0.28 mmol) was dissolved in dichloromethane (1 mL). Oxalyl chloride (0.36 g, 2.80 mmol) was slowly added dropwise under an ice bath, followed by DMF (0.002 g, 0.028 mmol). The mixture was allowed to react at room temperature for 2 h. After concentration, the crude product was added to a solution of 1h-2 (0.062 g, 0.41 mmol) and triethylamine (0.082 g, 0.81 mmol) in dichloromethane (1 mL) and allowed to react at room temperature overnight. The crude product was concentrated to afford the crude product, which was purified by silica gel column chromatography to afford a mixture of 34d-1a and 34d-1b (0.078 g, 59.38% yield).

[0449] Step 5: Preparation of Compound 34-1a and Compound 34-1b

[0450] A mixture of compounds 34d-1a and 34d-1b (0.078 g, 0.16 mmol) was dissolved in 7 M methanolic ammonia (5 mL) and allowed to react at room temperature for 18 h. The reaction was concentrated to afford a crude product, which was then purified by prep-HPLC (Condition 1) and lyophilized to afford a mixture of compounds 34-1a and 34-1b (0.034 g, 45.07% yield).

[0451] LCMS m / z=472.1[M+H] +

[0452] 1H NMR (400MHz, CDCl3): δ9.60(s,1H),8.45(d,1H),8.30(d,1H),8.11(s,1H),8.06(s,1H),7.25-7.18(m,1H),6.62(dd d,2H),5.88(s,1H),4.87(d,1H),4.55(dd,1H),3.85(s,3H),2.76(q,1H),1.93(s,3H),0.86(dd,J=6.9,2.3Hz,3H).

[0453] Example 35: Preparation of Compound 35-8a and Compound 35-8b

[0454] Step 1: Preparation of compound 35-2

[0455] 35-1 (2 g, 9.57 mmol) was dissolved in DMF (40 mL). NaH (574 mg, 14.36 mmol) was added under an ice bath and the reaction continued for 30 minutes. Deuterated iodomethane (2.77 g, 19.14 mmol) was added and the reaction was continued at room temperature under a nitrogen atmosphere for 5 hours. Water (100 mL) was added and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography to obtain 35-2 (1.1 g, 50.85% yield).

[0456] Step 2: Preparation of compound 35-3

[0457] 35-1 (400 mg, 1.77 mmol), (Bpin)2 (539.4 mg, 2.12 mmol), potassium acetate (521.1 mg, 5.31 mmol), and Pd(dppf)Cl2·DCM (114.6 mg, 0.18 mmol) were added to 1,4-dioxane (10 mL) and reacted at 100°C under nitrogen atmosphere for 5 h to obtain a reaction solution of 35-3.

[0458] Step 3: Preparation of compounds 35-4a and 35-4b

[0459] To the reaction mixture of 35-3 from the previous step were added 1e-2a and 1e-2b (713 mg, 1.77 mmol), Pd(PPh3)4 (102.3 mg, 0.09 mmol), potassium phosphate (1.13 g, 5.33 mmol), and water (1 mL). The mixture was reacted at 100°C under a nitrogen atmosphere for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The mixture was then purified on a silica gel column to afford a mixture of 35-4a and 35-4b (500 mg, 70.73% yield).

[0460] LCMS m / z=400.1[M+H] +

[0461] Step 4: Preparation of compounds 35-5a and 35-5b

[0462] A mixture of 35-4a and 35-4b (300 mg, 0.75 mmol) was dissolved in methanol (8 mL), and platinum oxide (52 mg) was added. The mixture was reacted at room temperature under a hydrogen atmosphere for 18 h. The mixture was filtered through celite, and the filtrate was concentrated and purified on a silica gel column to obtain a mixture of 35-5a and 35-5b (80 mg, 26.57% yield).

[0463] Step 5: Preparation of compounds 35-6a and 35-6b

[0464] A mixture of 35-5a and 35-5b (80 mg, 0.20 mmol) was dissolved in anhydrous ethanol (3 mL), and cesium carbonate (98 mg, 0.3 mmol) was added. The mixture was reacted at 50°C for 3 h. The reaction solution was cooled to room temperature and quenched by adding 1M hydrochloric acid (5 mL). The mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography to obtain a mixture of 35-6a and 35-6b (69 mg, 92.41% yield).

[0465] LCMS m / z=372.3[MH] -

[0466] Step 6: Preparation of compounds 35-7a and 35-7b

[0467] A mixture of 35-6a and 35-6b (50 mg, 0.13 mmol) was dissolved in a 2M solution of oxalyl chloride in dichloromethane (2 mL). DMF (0.002 g, 0.028 mmol) was added dropwise under an ice bath and allowed to react at room temperature for 2 h. After concentration, the crude product was added to a solution of methyl 4-aminopyridine-2-carboxylate (30 mg, 0.20 mmol) and triethylamine (39 mg, 0.39 mmol) in dichloromethane (2 mL) and allowed to react at room temperature overnight. The crude product was concentrated to afford the crude product, which was purified by silica gel column chromatography to afford a mixture of 35-7a and 35-7b (15 mg, 22.74% yield).

[0468] LCMS m / z=508.3[M+H] +

[0469] Step 7: Preparation of compounds 35-8a and 35-8b

[0470] A mixture of 35-7a and 35-7b (15 mg, 0.03 mmol) was dissolved in 7 M methanolic ammonia (1 mL) and allowed to react at room temperature for 18 h. The reaction mixture was concentrated to obtain a crude product, which was purified by silica gel column chromatography to afford a mixture of compounds 35-8a and 35-8b (5.64 mg, 38.17% yield).

[0471] LCMS m / z=493.4[M+H] +

[0472] Example 36: Preparation of Compound 36-1a and Compound 36-1b

[0473] Step 1: Preparation of compounds 36-1a and 36-1b

[0474] A mixture of 1h-2a and 1h-2b (50 mg, 0.14 mmol) was dissolved in a 2M solution of oxalyl chloride in dichloromethane (2 mL). DMF (0.002 g, 0.028 mmol) was added dropwise under an ice bath and allowed to react at room temperature for 2 h. After concentration, the crude product was added to a solution of 4-amino-2-methoxypyridine (26 mg, 0.21 mmol) and triethylamine (42 mg, 0.42 mmol) in dichloromethane (2 mL) and allowed to react at room temperature overnight. The crude product was concentrated to afford the crude product, which was purified by silica gel column chromatography to afford a mixture of 36-1a and 36-1b (55 mg, 82.45% yield).

[0475] LCMS m / z=477.1[M+H] +

[0476] Step 2: Preparation of compounds 36-2a and 36-2b

[0477] A mixture of 36-1a and 36-1b (45 mg, 0.10 mmol) was dissolved in THF (1 mL) and HCl (1 mL) and reacted at 60°C for 18 h. The reaction mixture was concentrated to obtain a crude product, which was then subjected to prep-HPLC (Condition 1) to obtain a mixture of compounds 36-2a and 36-2b (4 mg, 8.65% yield).

[0478] LCMS m / z=463.1[M+H] +

[0479] Example 37: Preparation of Compound 37-1a and Compound 37-1b

[0480] A mixture of 21-5a and 21-5b (70 mg, 0.19 mmol) was dissolved in tetrahydrofuran (3 mL). Triethylamine (120 mg, 1.14 mmol) and T3P (480 mg of 50% wt in EtOAc, containing 240 mg of 1-propylphosphonic anhydride, 0.76 mmol) were added sequentially. 3-Aminobenzamide (26 mg, 0.19 mmol) was added, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The reaction was quenched by the addition of aqueous sodium bicarbonate (10 mL), and extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was then subjected to prep-HPLC (Condition 1) to obtain a mixture of compound 37-1a and compound 37-1b (43 mg, 47.1% yield).

[0481] LCMS m / z=481.2[M+H] +

[0482] Example 38: Preparation of Compound 1-2a

[0483] Step 1: Preparation of compound 1h-2a

[0484] A 3.0 g mixture of compounds 1h-2a and 1h-2b was prepared by SFC and lyophilized to yield compounds 1h-2a (1.28 g, chiral HPLC retention time: 0.760 min) and 1h-2b (1.11 g, chiral HPLC retention time: 0.966 min). Chiral HPLC analysis method: (Instrument: SHIMADZU LC-30 AD, Chiralcel IG column. Preparation: The crude product was dissolved in acetonitrile to prepare a sample solution. Mobile phase: CO2 / 0.05% DEA in ethanol. Elution gradient: 5%-40%, elution time: 3 min).

[0485] SFC preparation conditions: Instrument: Waters 150 Prep-SFC A, preparative column: Chiralcel IG column. Preparation method: Dissolve the crude product in acetonitrile to a sample concentration of 2 mg / mL. Mobile phase: CO2 / ethanol, 10% ethanol; flow rate: 100 mL / min, elution time: 2 min.

[0486] Compound 1h-2a:

[0487] 1HNMR (400MHz, CDCl3): δ6.91-6.78(m,2H),4.53(d,1H),4.46-4.34(m,1H),4.02(d,3H),2.68-2.54(m,1H),1.85(s,3H),0.88-0.75(m,3H).

[0488] Step 2: Preparation of compounds 1i-2a

[0489] 1h-2a (1.0 g, 2.7 mmol) was dissolved in tetrahydrofuran (20 mL), and triethylamine (1.64 g, 16.20 mmol) and T3P (50% wt in EtOAc, 6.88 g, containing 1-propylphosphonic anhydride, 3.44 g, 10.79 mmol) were added sequentially. The mixture was stirred at room temperature for 15 minutes, and 1h-2 (0.62 g, 4.07 mmol) was added. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 hours. Saturated aqueous sodium bicarbonate (40 mL) was added, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain compound 1i-2a (0.919 g, 67.47% yield).

[0490] Step 3: Preparation of compound 1-2a

[0491] Compound 1-2a (0.87 g) was obtained by referring to the fourth step of Example 2;

[0492] The absolute configuration of compound 1-2a was confirmed by Micro-ED.

[0493] Example 39: Preparation of Compound 6-2a

[0494] 1h-2a (0.037 g, 0.1 mmol) was dissolved in tetrahydrofuran (3 mL), and triethylamine (0.061 g, 0.60 mmol), T3P (50% wt in EtOAc, 0.26 g, containing 1-propylphosphonic anhydride, 0.13 g, 0.40 mmol), and 6-2a-1 (0.023 g, 0.15 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford compound 6-2a (0.036 g, 71.08% yield).

[0495] 1HNMR (400MHz, CDCl3): δ9.69(s,1H),8.45-8.37(m,1H),8.10-8.04(m,1H),7.15-7.06(m,1H),6.98-6.88(m,2H),6.87-6 .78(m,1H),6.47(s,1H),4.84(d,1H),4.63-4.54(m,1H),4.08(d,3H),2.73-2.63(m,1H),1.93(s,3H),0.93-0.83(m,3H).

[0496] LCMS m / z=507.2[M+H] +

[0497] Example 40: Preparation of Compound 28-2a

[0498] 1h-2a (0.037 g, 0.1 mmol) was dissolved in tetrahydrofuran (5 mL), and triethylamine (0.061 g, 0.60 mmol) and T3P (50% wt in EtOAc, 0.26 g, containing 1-propylphosphonic anhydride, 0.13 g, 0.40 mmol) were added sequentially. 28-2a-1 (0.055 g, 0.41 mmol) was then added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added, and the mixture was extracted with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford compound 28-2a (0.106 g, 80.37% yield).

[0499] Example 41: Preparation of Compound 8-1a

[0500] 1h-2a (100 mg, 0.27 mmol) was separated and purified on a silica gel column according to the synthesis method of Example 8 to obtain compound 8-1a (95 mg, yield 62.9%).

[0501] LCMS m / z=543.2[M+H] +

[0502] 1H NMR (400MHz, CDCl3): δ8.54(s,1H),8.14-8.05(m,1H),7.74-7.65(m,1H),7.13(t,1H),7.04-6.95(m,1H),6.89-6.79 (m,1H),5.33(s,2H),4.67(d,1H),4.59-4.47(m,1H),4.04(d,3H),2.69-2.55(m,1H),1.91(s,3H),0.93-0.85(m,3H).

[0503] Example 42: Preparation of Compound 26-1a

[0504] Compound 1h-2a (100 mg, 0.27 mmol) was dissolved in tetrahydrofuran (5 mL), and triethylamine (164 mg, 1.62 mmol), T3P (50% wt in EtOAc, 686 mg, containing 1-propylphosphonic anhydride, 343 mg, 1.08 mmol), and 4-fluoro-3-(methylsulfonyl)aniline (76 mg, 0.405 mmol) were added sequentially. The mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added to the reaction system to quench the reaction. The mixture was then extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The residue was purified by silica gel column chromatography to afford compound 26-1a (132 mg, 90% yield).

[0505] Example 43: Preparation of Compound 27-1a

[0506] Using 1h-2a as substrate and referring to the synthesis conditions of Example 27, compound 27-1a was synthesized.

[0507] LCMS m / z=541.1[M+H] +

[0508] Example 44: Preparation of Compound 25-1a

[0509] 1h-2a (0.10 g, 0.27 mmol) was dissolved in tetrahydrofuran (5 mL), and triethylamine (0.16 g, 1.62 mmol) and T3P (50% wt in EtOAc, 0.69 g, containing 1-propylphosphonic anhydride, 0.345 g, 1.08 mmol) were added sequentially. 2-(Methylsulfonyl)pyridin-4-amine (0.070 g, 0.41 mmol) was then added, and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The reaction was quenched with aqueous sodium bicarbonate (10 mL) and extracted with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford 25-1a (0.05 g, 35.31% yield).

[0510] Example 45: Preparation of Compound 5-3a

[0511] Using 1h-2a as a substrate and referring to the synthesis method of Example 5, 5-3a was synthesized.

[0512] LCMS m / z=526.0[M+H] +

[0513] Example 46: Preparation of Compound 7-1a

[0514] Using 1h-2a as substrate and referring to the synthesis method of Example 7, compound 7-1a was synthesized.

[0515] Example 47: Preparation of Compound 19-2a

[0516] Using 1h-2a as a substrate and referring to the synthesis method of Example 19, compound 19-2a was synthesized.

[0517] LCMS m / z=478.50[M+H] +

[0518] Example 48: Preparation of Compound 48-1a

[0519] 1h-2a (0.037 g, 0.1 mmol) was dissolved in tetrahydrofuran (3 mL), and triethylamine (0.061 g, 0.60 mmol) and T3P (50% wt in EtOAc, 0.25 g, containing 1-propylphosphonic anhydride, 0.125 g, 0.40 mmol) were added sequentially. 48-1a-1 (0.021 g, 0.15 mmol) was then added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography to afford 48-1a (0.02 g, 40.53% yield).

[0520] LCMS m / z=494.2[M+H] +

[0521] 1 H NMR (400MHz, DMSO-d6): δ10.38(s,1H),7.66-7.62(m,1H),7.45-7.38(m,1H),7.22-7.14( m,1H),7.11-7.01(m,1H),5.26(t,1H),4.83(d,1H),4.52-4.44(m,3H),3.99(d,3H),2.65- 2.56(m,1H),1.85(s,3H),0.82-0.74(m,3H).

[0522] Example 49: Preparation of Compound 18-2a

[0523] Using 1h-2a as a substrate and referring to the synthetic method of Example 18, compound 18-2a was synthesized.

[0524] LCMS m / z=477.1[M+H] +

[0525] Example 50: Preparation of Compound 50

[0526] Step 1: Preparation of compound 50b

[0527] 50a (524 mg, 4.26 mmol) and imidazole (0.44 g, 6.39 mmol) were added to DMF (10 mL), followed by TBSCl (0.77 g, 5.11 mmol). The mixture was allowed to react at room temperature for 3 h. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to afford 50b (451 mg, 44.4% yield).

[0528] LCMS m / z=239.3[M+H]+

[0529] Step 2: Preparation of compound 50c

[0530] 1h-2a (50 mg, 0.14 mmol), 50b (67 mg, 0.28 mmol), T3P (50% wt in EtOAc 362 mg, containing 1-propylphosphonic anhydride 181 mg, 0.57 mmol), and TEA (85 mg, 0.84 mmol) were added to ethyl acetate (5 mL) and reacted at room temperature for 16 h. The reaction solution was quenched by adding aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated, and the residue was purified by silica gel column chromatography to afford 50c (24 mg, 29.02% yield).

[0531] LCMS m / z=591.5[M+H] +

[0532] Step 3: Preparation of Compound 50

[0533] 50c (24 mg, 0.041 mmol) was added to methanol (5 mL), and concentrated hydrochloric acid (1 mL) was slowly added. The reaction was allowed to react at room temperature for 3 h. The reaction solution was concentrated under reduced pressure, ethyl acetate (50 mL) was added, and then extracted with saturated aqueous sodium bicarbonate. The organic phase was separated, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by silica gel column chromatography to obtain compound 50 (8 mg, 38.90% yield).

[0534] LCMS m / z=477.2[M+H] +

[0535] Example 51: Preparation of Compound 33-1a

[0536] Step 1: Preparation of 33a-1a

[0537] Dissolve 1h-2a (100 mg, 0.27 mmol) in a 2M solution of oxalyl chloride in dichloromethane (2 mL). Add DMF (0.002 g, 0.028 mmol) dropwise under an ice bath and allow to react at room temperature for 2 h. After concentration, the crude product was added to a solution of 33-1a-1 (prepared according to WO2022121517A1) (61 mg, 0.27 mmol) and triethylamine (82 mg, 0.81 mmol) in dichloromethane (2 mL) and allowed to react at room temperature overnight. Concentration afforded the crude product, which was then purified by silica gel column chromatography to afford 33a-1a (100 mg, 64.24% yield).

[0538] Step 2: Preparation of compound 33-1a

[0539] To compound 33a-1a (100 mg, 0.17 mmol) was added a 4 M dioxane hydrochloride solution (1 mL), and the mixture was allowed to react at room temperature under a nitrogen atmosphere for 18 h. The crude product was concentrated and purified by prep-HPLC (condition 2) to afford compound 33-1a (70 mg, 76.75% yield).

[0540] Example 52: Preparation of Compound 36-2a

[0541] Using 1h-2a as substrate and referring to the synthesis method of Example 36, compound 36-2a was synthesized.

[0542] LCMS m / z=463.1[M+H] +

[0543] Example 53: Preparation of Compound 20-1a

[0544] 1h-2a (100 mg, 0.27 mmol) was dissolved in tetrahydrofuran (5 mL), and triethylamine (164 mg, 1.62 mmol) and T3P (50% wt in EtOAc 686 mg, containing 1-propylphosphonic anhydride 343 mg, 1.08 mmol) were added sequentially. 3-Aminopyridine oxide (60 mg, 0.53 mmol) was added, and the mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. The reaction solution was quenched by adding sodium bicarbonate aqueous solution and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. Compound 20-1a (25 mg, 19.84% yield) was obtained by separation and purification on a silica gel column.

[0545] LCMS m / z=463.1[M+H] +

[0546] Example 54: Preparation of Compound 54

[0547] 1h-2a (100 mg, 0.27 mmol) and 54-1 (69 mg, 0.40 mmol) were synthesized according to the synthesis method of Example 22 to obtain compound 54 (90 mg, yield 63.4%).

[0548] LCMS m / z=524.1[M+H] + ;

[0549] Example 55: Preparation of Compound 55

[0550] Compound 6-1a (40 mg, 0.077 mmol) was added to a 1 mL aqueous solution of lithium hydroxide (5 mg, 0.19 mmol), followed by 1 mL of methanol. The mixture was allowed to react at 40°C for 16 h. The reaction mixture was concentrated under reduced pressure to afford the crude product, which was then purified by prep-HPLC (condition 2) to afford compound 55 (10 mg, 25.56% yield).

[0551] LCMS m / z=508.1[M+H] +

[0552] Example 56: Preparation of Compound 56

[0553] 1h-2a (100 mg, 0.27 mmol) and 56-1 (68 mg, 0.405 mmol) were separated and purified on a silica gel column according to the synthesis method of Example 22 to obtain compound 56 (137 mg, yield 94.4%).

[0554] LCMS m / z=522.5[M+H] + ;

[0555] Example 57: Preparation of Compound 57

[0556] Preparation of compound 57

[0557] 1h-2a (74 mg, 0.2 mmol) and 57-1 (50.7 mg, 0.3 mmol) were separated and purified on a silica gel column according to the synthesis method of Example 22 to obtain compound 57 (87 mg, yield 81.7%).

[0558] LCMS m / z=522.5[M+H] + ;

[0559] Example 58: Preparation of Compound 58

[0560] Preparation of compound 58

[0561] 1h-2a (100 mg, 0.27 mmol) and 58-1 (69 mg, 0.41 mmol) were prepared by Prep-HPLC (condition 2) according to the synthesis method of Example 22 to obtain trifluoroacetate salt of compound 58 (36 mg, yield 25.5%).

[0562] LCMS m / z=523.1[M+H] + ;

[0563] 1H NMR (400MHz, CDCl3) δ11.37(s,1H),8.71(d,1H),8.61-8.52(m,1H),8.16-8.07(m,1H),6.91-6.75(m,2H),4.81 (d,1H),4.65-4.57(m,1H),4.09(d,3H),2.78-2.65(m,1H),2.06-1.96(m,6H),1.93(s,3H),0.94-0.82(m,3H).

[0564] 1h-2a (254 mg, 0.69 mmol) and 58-1 (180 mg, 1.03 mmol), triethylamine (420 mg, 4.14 mmol), and T3P (50% wt in EtOAc, 1.73 g, containing 0.87 g, 2.76 mmol, of 1-propylphosphonic anhydride) were added to tetrahydrofuran (10 mL) and allowed to react at room temperature for 16 hours. Aqueous sodium bicarbonate (20 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was then purified on a silica gel column to afford compound 58 (220 mg, 60.4% yield).

[0565] Example 59: Preparation of Compound 59-a

[0566] Step 1: Preparation of compounds 21-5P1 and 21-5P2

[0567] 1.3 g of a mixture of compound 21-5a and compound 21-5b was separated by SFC to give compound 21-5P1 (552 mg, chiral HPLC retention time: 0.736 min) and compound 21-5P2 (504 mg, chiral HPLC retention time: 1.033 min).

[0568] Compound 21-5P1 is one of the above 21-5a and 21-5b; and is an enantiomer of compound 21-5P2, that is, when the structure of compound 21-5P1 is the structure of formula 21-5a, the structure of compound 21-5P2 is the structure of formula 21-5b; when the structure of compound 21-5P1 is the structure of formula 21-5b, the structure of compound 21-5P2 is the structure of formula 21-5a.

[0569] SFC preparation conditions:

[0570] Instrument: Waters 150 Prep-SFC C, preparative column: Chiral IC column. Preparation: Dissolve the crude product in acetonitrile to a 10 mg / mL sample solution. Mobile phase: CO2 / 0.1% NH3·H2O methanol solution, methanol content: 15%; elution time: 8 min.

[0571] Chiral test method: (Instrument: SHIMADZU LC-30 AD sf, Preparative column: Chiral IC column. Preparation method: Dissolve the crude product in acetonitrile to prepare the sample solution. Mobile phase system: carbon dioxide / 0.05% DEA in methanol solution. Elution gradient: 5%-40%; flow rate: 3.0 mL / min, elution time: 3 min).

[0572] Step 2: Preparation of compound 59-a

[0573] 21-5P1 (50 mg, 0.14 mmol) was dissolved in a 2M solution of oxalyl chloride in dichloromethane (2 mL). DMF (0.002 g, 0.028 mmol) was added dropwise under an ice bath and allowed to react at room temperature for 2 h. After concentration, the crude product was added to a solution of 8-1a-1 (40 mg, 0.21 mmol) and triethylamine (42.5 mg, 0.42 mmol) in dichloromethane (2 mL) and allowed to react at room temperature overnight. The crude product was concentrated and purified by silica gel column chromatography to afford 59-a (50 mg, 66.8% yield). Compound 59-a exhibited the same chiral orientation as 21-5P1.

[0574] LCMS m / z=535.0[M+H] +

[0575] Referring to the preparation method of 59-a (amidation reaction does not cause configuration change), the target compounds described in the following table were prepared (keeping the configuration consistent with the substrate).

[0576] Example 70: Preparation of Compound 70-a

[0577] Step 1: Compounds 31h-1P1 and 31h-1P2

[0578] The mixture of compounds 31h-1a and 31h-1b (1 gg) was separated by SFC to give compound 31h-1P1 (412 mg, retention time: 1.589 min) and compound 31h-1P2 (430 mg, retention time: 1.778 min).

[0579] Compound 31h-1P1 is one of the above 31h-1a and 31h-1b; and is an enantiomer of compound 31h-1P2, that is, when the structure of compound 31h-1P1 is the structure of formula 31h-1a, the structure of compound 31h-1P2 is the structure of formula 31h-1b; when the structure of compound 31h-1P1 is the structure of formula 31h-1b, the structure of compound 31h-1P2 is the structure of formula 31h-1a.

[0580] SFC preparation conditions:

[0581] Instrument: SFC Prep 150 AP, Preparative Column: Daicel AD-H (19 mm × 250 mm). Preparation: Sample was dissolved in methanol and filtered through a 0.45 μm filter to prepare the sample solution. Mobile phase: CO2 / ethanol, 8% ethanol; Flow rate: 40 ml / min.

[0582] Step 2: Preparation of compound 70-a

[0583] 31h-1P1 (50 mg, 0.14 mmol) was dissolved in ethyl acetate (3 mL), and triethylamine (85 mg, 0.84 mmol), T3P (50% wt in EtOAc, 360 mg, containing 180 mg, 0.56 mmol, of 1-propylphosphonic anhydride), and 6-2a-1 (43 mg, 0.28 mmol) were added sequentially. The mixture was reacted at room temperature under a nitrogen atmosphere for 18 h. Aqueous sodium bicarbonate (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was then purified on a silica gel column to afford 70-a (6.28 mg, 9.11% yield).

[0584] LCMS m / z=493.2[M+H] +

[0585] Referring to the preparation method of 70-a (amidation reaction does not cause configuration change), the target compounds described in the following table were prepared (keeping the configuration consistent with the substrate).

[0586] Example 76: Preparation of Compounds 76-8a and 76-8b

[0587] Step 1: Preparation of compound 76-2

[0588] 76-1 (3.8 g, 20.0 mmol), 3-bromo-2-methylpropene (3.24 g, 24.0 mmol), and potassium carbonate (5.53 g, 40.09 mmol) were added to acetonitrile (80 mL) and reacted at 60°C under a nitrogen atmosphere for 12 h. The reaction solution was cooled to room temperature and filtered through celite. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford 76-2 (4.5 g, 91.8% yield).

[0589] Step 2: Preparation of compound 76-3

[0590] 76-2 (4.5 g, 18.36 mmol) was added to dichloromethane (180 mL), and aluminum chloride (120 mg, 0.9 mmol) was added in an ice bath. The reaction was allowed to react for 2 h. The reaction solution was quenched by adding aqueous sodium bicarbonate solution. The organic phase was separated, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified on a silica gel column to afford 76-3 (3.07 g, 68.2% yield).

[0591] Step 3: Preparation of compounds 76-4a and 24-4b

[0592] 76-3 (290 mg, 1.2 mmol), (Bpin)2 (370 mg, 1.44 mmol), potassium acetate (240 mg, 2.4 mmol), and Pd(dppf)Cl2·DCM (49 mg, 0.06 mmol) were added to 1,4-dioxane (8 mL) and reacted at 100°C under a nitrogen atmosphere for 6 h. The reaction solution was cooled to room temperature and filtered through celite to obtain a filtrate. To the filtrate were added water (3 mL), a mixture of 1e-2a and 1e-2b (480 mg, 1.2 mmol), potassium phosphate (760 mg, 3.58 mmol), and Pd(PPh3)4 (57.8 mg, 0.05 mmol), and the reaction was continued at 100°C under a nitrogen atmosphere for 4 h. The reaction solution was cooled to room temperature and filtered through celite. The filtrate was concentrated under reduced pressure and purified by silica gel column separation to obtain a mixture of 76-4a and 76-4b (280 mg, yield 55.7%).

[0593] Step 4: Preparation of 76-5a and 76-5b

[0594] A mixture of 76-4a and 76-4b (240 mg, 0.57 mmol) was dissolved in methanol (15 mL), and platinum dichloride (50 mg, 0.19 mmol) was added. The mixture was reacted at room temperature under a hydrogen atmosphere for 20 h. The reaction solution was filtered through celite, and the filtrate was concentrated and purified on a silica gel column to obtain a mixture of 76-5a and 76-5b (133 mg, 55.5% yield).

[0595] Step 5: Preparation of 76-6a and 76-6b

[0596] A mixture of 76-5a and 76-5b (143 mg, 0.34 mmol) was dissolved in anhydrous ethanol (5 mL), and cesium carbonate (170 mg, 0.51 mmol) was added. The mixture was reacted at 50°C for 5 h. The reaction solution was cooled to room temperature and concentrated under reduced pressure. 1M hydrochloric acid (5 mL) was added to quench the mixture, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified on a silica gel column to obtain a mixture of 76-6a and 76-6b (124 mg, 92.9% yield).

[0597] LCMS m / z=391-3[MH] -

[0598] Step 6: Preparation of 76-7a and 76-7b

[0599] A mixture of 76-6a and 76-6b (124 mg, 0.32 mmol) was dissolved in ethyl acetate (6 mL). Triethylamine (200 mg, 1.95 mmol), T3P (788 mg of 50% wt in EtOAc, containing 394 mg of 1-propylphosphonic anhydride, 1.29 mmol), and 1h-2 (73 mg, 0.48 mmol) were added sequentially. The mixture was allowed to react at room temperature under a nitrogen atmosphere for 20 h. Aqueous sodium bicarbonate (20 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was then purified on a silica gel column to afford a mixture of 76-7a and 76-7b (50 mg, 29.7% yield).

[0600] LCMS m / z=527.2[M+H] +

[0601] Step 7: Preparation of a mixture of compound 76-8a and compound 76-8b

[0602] A mixture of 76-7a and 76-7b (50 mg, 0.095 mmol) was dissolved in 7M methanolic ammonia solution (3 mL) and allowed to react at room temperature for 4 h. The reaction system was concentrated to obtain a crude product, which was purified by silica gel column chromatography to afford a mixture of compounds 76-8a and 76-8b (18 mg, 36.8% yield).

[0603] LCMS m / z=512.2[M+H] +

[0604] 1H NMR(400MHz, CDCl3)δ9.91(s,1H),8.45(d,1H),8.40-8.30(m,1H),8.18(d,1H),8.00(d,1H),7.07-6.92(m,1H),6.51(t,1H),5.91 (s,1H),5.11(d,1H),4.44-4.29(m,1H),3.00(s,2H),2.79-2.68(m,1H),1.90(s,3H),1.47(s,3H),1.42(s,3H),1.00-0.92(m,3H).

[0605] Example 77: Preparation of Compound 77

[0606] Step 1: Preparation of compound 77b

[0607] 77a (3.04 g, 20.0 mmol), (Boc)2O (4.8 g, 22 mmol), and 4-dimethylaminopyridine (244 mg, 2.0 mmol) were added to dichloromethane (70 mL) and allowed to react at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure and purified by column chromatography to afford 77b (2.38 g, 33.8% yield).

[0608] LCMS m / z=353.4[M+H] +

[0609] Step 2: Preparation of compound 77c

[0610] 77b (352 mg, 1.0 mmol) was added to dichloromethane (10 mL), placed in an ice bath, and m-chloroperbenzoic acid (516 mg, 3.0 mmol) was added. The reaction was continued at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure and purified on a silica gel column to obtain 77c (211 mg, 57.3% yield).

[0611] LCMS m / z=369.2[M+H] +

[0612] Step 3: Preparation of compound 77d

[0613] 77c (134 mg, 0.364 mmol) was added to dichloromethane (2 mL), and a 4M solution of hydrogen chloride in 1,4-dioxane (4 mL) was added to the system. The reaction mixture was allowed to react at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and then dichloromethane (2 mL) was added. A 4M solution of hydrogen chloride in 1,4-dioxane (4 mL) was added to the system and the reaction mixture was allowed to react for 2 hours. The reaction mixture was cooled and concentrated under reduced pressure to obtain 77d (71 mg).

[0614] LCMS m / z=169.1[M+H] +

[0615] Step 4: Preparation of compound 77e

[0616] 77d (71 mg) was dissolved in tetrahydrofuran (8 mL), followed by the addition of triethylamine (121.4 mg, 1.2 mmol) and T3P (509 mg of 50% wt in EtOAc, containing 254.5 mg of 1-propylphosphoric anhydride, 0.8 mmol). Finally, substrate 1h-2a (74 mg, 0.2 mmol) was added to the system. After addition, the reaction was allowed to proceed at room temperature under a nitrogen atmosphere for 20 hours. Aqueous sodium bicarbonate (20 mL) was added to the reaction system to quench the reaction. The reaction was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was then purified on a silica gel column to afford 77e (81 mg, 77.8% yield).

[0617] LCMS m / z=521.1[M+H] +

[0618] Step 5: Preparation of Compound 77

[0619] Substrate 77e (81 mg, 0.155 mmol) was dissolved in 7 M methanolic ammonia solution (10 mL) and reacted at room temperature for 2 hours. The reaction system was concentrated to obtain a crude product, which was purified by silica gel column chromatography to afford compound 77 (42 mg, 53.6% yield).

[0620] LCMS m / z=506.1[M+H] +

[0621] Biological Test Example 1

[0622] Nav1.8 manual patch clamp test

[0623] (1) Cell culture

[0624] The CHO cell line stably expressing human Nav1.8 was cultured in Ham's F-12 medium containing 10% fetal bovine serum, 10 μg / mL Blasticidin, 200 μg / mL Hygromycin B, and 100 μg / mL Zeocin. The cell culture temperature was 37°C and the carbon dioxide concentration was 5%. The old culture medium was removed and rinsed once with PBS, then 1 mL of 0.25%-Trypsin-EDTA solution was added and incubated at 37°C for about 1.5 minutes. When the cells detached from the bottom of the dish, complete culture medium preheated to 37°C was added. The cell suspension was gently pipetted with a pipette to separate the aggregated cells. The cell suspension was transferred to a sterile centrifuge tube and centrifuged at 1000 rpm for 5 minutes to collect the cells. The cells were inoculated in 6 cm cell culture dishes, with 2.5×10 cells in each cell culture dish. 5 cells (final volume 5 mL) for expansion or maintenance culture. To maintain the electrophysiological activity of the cells, the cell density should not exceed 80%. Before patch clamp testing, the cells were separated with 0.25%-Trypsin-EDTA and 6.5×10 3 Cells were plated onto coverslips and cultured in 24-well plates (final volume 500 μL) and assayed after 18 hours.

[0625] (2) Compound preparation

[0626] Compounds were dissolved in dimethyl sulfoxide (DMSO) and prepared into 30 mM DMSO stock solutions. The stock solutions were diluted to the assay concentrations using extracellular fluid (140 mM NaCl, 3.5 mM KCl, 1 mM MgCl2·6H2O, 2 mM CaCl2·2H2O, 10 mM D-Glucose, 10 mM HEPES, and 1.25 mM NaH2PO4·2H2O, pH adjusted to 7.4 with NaOH). The final DMSO concentration for all assay samples was 0.1%.

[0627] (3) Electrophysiological test

[0628] First, a recording electrode is drawn from a capillary glass tube using a microelectrode puller. The electrode, filled with intracellular solution (50mM CsCl, 10mM NaCl, 10mM HEPES, 60mM CsF, and 20mM EGTA, with CsOH adjusted to pH 7.2), is then placed in a microelectrode holder. Under an inverted microscope, the microelectrode manipulator is used to immerse the electrode in the extracellular solution and record the electrode resistance (Rpip). The electrode is then slowly brought into contact with the cell surface, and negative pressure is applied to form a GΩ seal. Fast capacitance compensation is then performed, and negative pressure is continued to rupture the cell membrane, establishing whole-cell recording mode. Finally, slow capacitance compensation is performed, and experimental parameters such as series resistance (Rs) are recorded. No leakage compensation is applied. Drug administration begins after the Nav1.8 current recorded in the whole cell stabilizes, and each drug concentration is applied for approximately 5 minutes (or until the current stabilizes). A coverslip containing cells was placed in a recording bath under an inverted microscope. A blank control solution and a working solution of the test compound were gravity-flown through the recording bath, exposing the cells to the current. A peristaltic pump was used for fluid exchange. The current measured in the absence of compound in the recording bath served as the control. All electrophysiological experiments were performed at room temperature. The percentage of peak current produced before and after compound treatment was calculated to determine the inhibitory effect of Nav1.8 on the cells.

[0629] The voltage stimulation protocol for whole-cell patch clamp recording of Nav1.8 sodium currents is as follows: After forming a whole-cell seal, the cell voltage is clamped at -120 mV. First, the voltage is stepped from -110 mV to -30 mV in 10 mV steps, maintained for 5 s, and then a 0 mV depolarizing pulse is applied to obtain the half-inactivation voltage (Vhalf). Then, Vhalf is used as the stimulation voltage and maintained for 5 s. The voltage is then returned to -120 mV and maintained for 20 ms. A depolarizing pulse (TP2) is then applied to 0 mV for 50 ms to detect the sodium current in the half-inactivation state. Finally, the clamping voltage is returned to -120 mV, and data are repeatedly collected every 20 ms to observe the effect of the drug on the peak sodium current. The experimental data are acquired by an EPC 10 amplifier (HEKA) and stored in PatchMaster (HEKA) software.

[0630] Table 1 IC inhibitory activity of test compounds on hNav1.8 50

[0631] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good Nav1.8 inhibitory activity. Specifically, compound 31-1P1 has an IC50 of 0.0412 nM against hNav1.8.

[0632] Biological test example 2: rat pharmacokinetic test

[0633] Test animals: Male SD rats, about 220 g, 6 to 8 weeks old, 6 rats per compound.

[0634] Experimental design: On the day of the experiment, 24 SD rats were randomly divided into groups according to body weight. They were fasted but not watered for 12-14 hours before administration and fed 4 hours after administration.

[0635] Table 2. Dosing Information

[0636] Note: Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline; Oral administration solvent: 0.5% MC

[0637] (DMA: dimethylacetamide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; MC: methylcellulose)

[0638] Before and after drug administration, 0.10 mL of blood was collected via the orbital cavity under isoflurane anesthesia. The blood was placed in an EDTAK2 centrifuge tube and centrifuged at 5000 rpm at 4°C for 10 minutes to collect plasma. Blood was collected from both the intravenous and oral gavage groups at 0, 5, 15, 30 minutes, and 1, 2, 4, 6, 8, and 24 hours. All samples were stored at -80°C prior to analysis and quantitative analysis was performed using LC-MS / MS.

[0639] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good oral performance in rats.

[0640] Biological test example 3: mouse pharmacokinetic test

[0641] Test animals: C57 mice, 22-25 g, 6 mice / compound.

[0642] Experimental Design: On the day of the experiment, C57 mice were randomly divided into groups according to body weight. They were fasted but not watered for 12-14 hours before administration and fed 4 hours after administration.

[0643] Table 3. Dosing Information

[0644] Note: Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline; Oral administration solvent: 0.5% MC

[0645] (DMA: dimethylacetamide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; MC: methylcellulose)

[0646] Before and after drug administration, 0.06 mL of blood was collected via the orbital cavity under isoflurane anesthesia. The blood was placed in an EDTAK2 centrifuge tube and centrifuged at 5000 rpm at 4°C for 10 minutes to collect plasma. Blood was collected from both the intravenous and oral gavage groups at 0, 5, 15, 30 minutes, and 1, 2, 4, 7, 24, and 48 hours. All samples were stored at -80°C prior to analysis and quantitative analysis was performed using LC-MS / MS.

[0647] Table 3-1 Pharmacokinetic results of test compounds in mice

[0648] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good oral efficacy in mice.

[0649] Biological Test Example 4: Beagle Dog Pharmacokinetic Test

[0650] Experimental animals: Male beagle dogs, weighing about 8-11 kg, 6 per compound, purchased from Beijing Masi Biotechnology Co., Ltd.

[0651] Test Method: On the day of the test, 12 beagle dogs were randomly divided into groups based on body weight. They were fasted but not watered for 12-14 hours prior to dosing and fed 4 hours after dosing. Dosing was performed according to Table 4.

[0652] Table 4. Dosing Information

[0653] Note: Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline; Oral administration solvent: 0.5% MC

[0654] (DMA: dimethylacetamide; Solutol: polyethylene glycol-15-hydroxystearate; Saline: normal saline; MC: methylcellulose solution;)

[0655] Before and after dosing, 1 ml of blood was collected from the jugular vein or limb vein into an EDTAK2 centrifuge tube. The samples were centrifuged at 5000 rpm at 4°C for 10 minutes, and plasma was collected. For both the intravenous and oral administration groups, blood was collected at the following time points: 0, 5, 15, 30 minutes, and 1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours. All samples were stored at -80°C prior to analysis and quantitative analysis was performed using LC-MS / MS.

[0656] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good oral performance in dogs.

[0657] Biological Test Example 5: Monkey Pharmacokinetic Test

[0658] Experimental animals: Male cynomolgus monkeys, 3-5 kg, 3-6 years old, 6 per compound, purchased from Suzhou Xishan Biotechnology Co., Ltd.

[0659] Experimental method: On the day of the experiment, 6 monkeys were randomly divided into groups according to body weight. They were fasted but not watered for 14-18 hours before administration and fed 4 hours after administration.

[0660] Table 5. Dosing Information

[0661] Note: Intravenous administration solvent: 5% DMA + 5% Solutol + 90% Saline; Oral administration solvent: 0.5% MC (containing 0.5% Tween 80);

[0662] *Dosage is based on the free base.

[0663] Before and after dosing, 1.0 mL of blood was collected from a limb vein and placed in an EDTAK2 centrifuge tube. The samples were centrifuged at 5000 rpm at 4°C for 10 minutes, and plasma was collected. Blood was collected from both the intravenous and oral administration groups at the following time points: 0, 5, 15, 30 minutes, and 1, 2, 4, 6, 8, 10, 12, and 24 hours. All samples were stored at -80°C prior to analysis and quantitative analysis was performed using LC-MS / MS.

[0664] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good oral performance in monkeys.

[0665] Biological Test Example 6: CYP450 Enzyme Inhibition Test

[0666] The purpose of this study was to evaluate the effects of test substances on the activities of five isoenzymes of cytochrome P450 (CYP) in human liver microsomes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) using an in vitro test system. Specific probe substrates for the CYP450 isoenzymes were incubated with human liver microsomes and varying concentrations of the test substances. Reduced nicotinamide adenine dinucleotide phosphate (NADPH) was added to initiate the reaction. After the reaction, the samples were processed and the metabolites produced by the specific substrates were quantitatively detected by liquid chromatography-tandem mass spectrometry (LC-MS / MS). Changes in CYP enzyme activity were measured, and the IC values ​​were calculated. 50 The inhibitory potential of the test substance on each CYP enzyme isoform was evaluated.

[0667] Conclusion: The compounds of the present invention, such as the example compounds, have weak CYP inhibition. For example, the IC50 of compound 58 against five CYP isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) is greater than 30 μM.

[0668] Biological Test Example 7: Caco2 Permeability Test

[0669] The experiment used Caco-2 cell monolayers in 96-well Transwell plates, incubated in triplicate. Transport buffer (HBSS, 10 mM HEPES, pH 7.4 ± 0.05) containing the compound of the invention (2 μM) or the control compounds digoxin (10 μM), nadolol (2 μM), and metoprolol (2 μM) was added to the apical or basolateral wells of the cell monolayer. Transport buffer containing DMSO was added to the corresponding receiving wells. After incubation at 37 ± 1°C for 2 hours, the cell plate was removed and appropriate samples were taken from the apical and basolateral wells to a new 96-well plate. Proteins were then precipitated by adding acetonitrile containing an internal standard. Samples were analyzed using LC-MS / MS to determine the concentrations of the compound of the invention and the control compound. The concentration data were used to calculate the apparent permeability coefficients for transport from the apical to basolateral side of the cell monolayer and from the basolateral to apical side, thereby calculating the efflux rate. The integrity of the cell monolayer after 2 hours of incubation was assessed by leakage of Lucifer Yellow.

[0670] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good permeability.

[0671] Biological Test Example 8: Spinal Nerve Ligation (SNL)-Induced Neuropathic Pain Model in Mice

[0672] Male C57BL / 6J mice purchased from Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd. were adaptively raised for one week before establishing the model. The specific establishment method is as follows:

[0673] (1) Sterilization of surgical instruments and ligatures;

[0674] (2) Mice were anesthetized with isoflurane and placed in the prone position on the operating table;

[0675] (3) The mouse was skinned near the hip bone and an incision of approximately 2 cm was made along the spine.

[0676] (4) Separate the fascia along the spine, bluntly separate the muscles, and expose the L5 transverse process;

[0677] (5) Use forceps to carefully bite off the L5 transverse process and expose the L5 spinal nerve;

[0678] (6) Carefully separate the L5 nerve with a glass needle and ligate it with a 5-0 ligature.

[0679] (7) Suture the muscles and skin and disinfect with iodine;

[0680] The day after modeling, mice with unsuccessful modeling were eliminated (sign of successful modeling: the hind paw of the mouse curled up). After modeling, the mice were stroked for 3 to 5 minutes every day to ensure that the animals were familiar with the experimenter. Then, the mice were placed on a metal pain test frame to adapt for 40 to 60 minutes. After the third day, after environmental adaptation, the mice were placed on a metal pain test frame to adapt for 40 to 60 minutes. Pre-dose baseline values ​​(Ascending test) were obtained for test animals (0.16, 0.4, 0.6, 1.0, 1.4, and 2.0 g). Each animal was measured twice, with at least 5 minutes between measurements, and the average was calculated. The animals were then grouped according to baseline values ​​(10 animals per group). After grouping, the test compound (3 and 30 mg / kg) or vehicle (0.5% methylcellulose) was administered orally, and the mechanical pain threshold (MPT) of the mice was measured at various time points after administration. Time-MPT curves were plotted and statistically analyzed using GraphPad 8.3.0.

[0681] Conclusion: According to the area under the time-MPT curve analysis, the compounds of the present invention, such as the example compounds, have significant analgesic effects. For example, compound 6-2a has significant analgesic effects at a dose of 3 mg / kg or 30 mg / kg.

Claims

1. A compound or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the compound is selected from the group consisting of compounds represented by general formula (I), Q1 is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, C 5-10 carbocyclic group, 5- to 10-membered heterocyclic group or The aryl, heteroaryl, carbocyclic or heterocyclic group is optionally substituted by 1 to 5 R q replace; R Q1 Selected from H, COOH, NR q1 R q2 、-C(=O)NR q1 R q2 、-S(=O)2NR q1 R q2 、OH、=O、-OR q1 、-C(=O)R q1 、-S(=O)2R q1 、-S(=O)(=NR q1 )R q2 or-P(=O)R q1 R q2 ; R q1 、R q2 Each independently selected from H, C 1-6 Alkyl, C 3-6 Carbocyclic group, 4 to 7 membered heterocyclic group, said alkyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace; Alternatively, R q1 、R q2 directly connected to form a 4- to 7-membered heterocyclic group, which is optionally substituted by 1 to 4 R k replace; B is selected from C 6-10 Aryl, 5- to 10-membered heteroaryl, C 5-10 Carbocyclic group, 5 to 10 membered heterocyclic group, the aryl, heteroaryl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R B replace; R 1 、R 2 Each independently selected from H, halogen, CN, OH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-6 Carbocyclic group, 3 to 7 membered heterocyclic group, the alkyl, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H; R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, halogen, CN, OH, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7 Carbocyclic group, -OC 3-7 Carbocyclyl, 3- to 7-membered heterocyclyl, or -P(=O)R q1 R q2 The alkyl, alkenyl, alkynyl, carbocyclic or heterocyclic group is optionally substituted by 1 to 4 R k replace; R k Selected from deuterium, =O, halogen, CN, OH, NH2, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -OC 3-6 Carbocyclic group, -O-3 to 7 membered heterocyclic group, -NH-C 3-6 Carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 1-4 Alkylene-C 3-6 Carbocyclic group, -C 1-4 Alkylene-3 to 7 membered heterocyclic group, C 3-6 Carbocyclic group, 3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent.

2. The compound according to claim 1 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, R q1 、R q2 Each independently selected from H, C 1-4 Alkyl, C 3-6 Carbocyclic group, 4 to 7 membered heterocyclic group, the alkyl group, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace; Alternatively, R q1 、R q2 directly connected to form a 4- to 7-membered heterocyclic group, which is optionally substituted by 1 to 4 R k replace; Q1 is selected from phenyl, benzo 4-6 Carbocyclic group, benzo 4 to 6 heterocyclic group, 5 to 6 membered heteroaryl, 8 to 10 membered heteroaryl or The Q1 is optionally replaced by 1 to 4 R q replace; B is selected from phenyl, benzo 4-6 Carbocyclic group, benzo 4 to 6 heterocyclic group, 5 to 6 membered heteroaryl, 8 to 10 membered heteroaryl, wherein B is optionally substituted by 1 to 4 R B replace; R 1 、R 2 Each independently selected from H, halogen, CN, OH, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 3-6 Carbocyclic group, 3 to 7 membered heterocyclic group, the alkyl, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H; R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, halogen, CN, OH, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, C 3-7 Carbocyclic group, -OC 3-7 Carbocyclyl, 3- to 7-membered heterocyclyl, or -P(=O)R q1 R q2 The alkyl, alkenyl, alkynyl, carbocyclic or heterocyclic group is optionally substituted by 1 to 4 R k replace; R k Selected from deuterium, =O, halogen, CN, OH, NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -OC 1-4 Alkyl, -SC 1-4 Alkyl, -OC 3-6 Carbocyclic group, -O-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

3. The compound according to claim 2, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, R q1 、R q2 Each independently selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or cyclopentyl, wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted by 1 to 4 R k replace; R 1 、R 2 Each independently selected from H, F, Cl, Br, cyano, methyl, ethyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl, wherein the methyl, ethyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl is optionally substituted by 1 to 4 R k Replace, provided that R 1 、R 2 Not at the same time H; B is selected from or phenyl, said B is optionally replaced by 1 to 5 R B replace; R 3 、R 4 、R q 、R B Each independently selected from H, deuterium, F, Cl, Br, cyano, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropyloxy, methylthio, cyclopropyl, cyclopropyloxy, cyclobutyl, vinyl, ethynyl, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl), wherein the methyl, ethyl, isopropyl, methoxy, ethoxy, isopropyloxy, methylthio, cyclopropyl, cyclobutyl, vinyl, ethynyl is optionally substituted by 1 to 4 R k replace; R k is selected from deuterium, =O, F, Cl, Br, I, CN, OH, NH2, NH(CH3), NH(CH2CH3), N(CH3)2, N(CH2CH3)2, methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally substituted by 1 to 4 groups selected from deuterium, halogen, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

4. The compound according to claim 3, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein: Q1 is selected from The Q1 is optionally replaced by 1 to 5 R q replace; R 3 、R 4 Each independently selected from H, methyl, ethyl, CH2F, CHF2, CF3; R 1 、R 2 Each is independently selected from H, methyl, ethyl, CH2F, CHF2, CF3, provided that R 1 、R 2 Not at the same time H; R q 、R B Each independently selected from H, F, Cl, Br, cyano, CH2F, CHF2, CF3, -OCH2F, -OCHF2, -OCF3, -OCD3, methyl, -S-methyl, -S-CF3, ethyl, isopropyl, ethynyl, methoxy, ethoxy, isopropyloxy, propyloxy, cyclopropyl, -O-cyclopropyl, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl), wherein the methyl, ethyl, isopropyl, ethynyl, methoxy, ethoxy, isopropyloxy, propyloxy, cyclopropyl is optionally substituted by 1 to 4 R k replace; R k Selected from deuterium, F, Cl, Br, I, CN, OH, -CH2OH, methyl, ethyl, vinyl, ethynyl, methoxy, ethoxy, methylthio, -O-cyclopropyl, -NH-cyclopropyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.

5. The compound according to claim 4, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein: Selected from The Q1 is optionally replaced by 1 to 3 R q replace; R qa Selected from -CH2OH, -CF2CH2OH, NH2, -P(=O)(CH3)2, -P(=O)(CH2CH3)2, -P(=O)(CH3)(cyclopropyl), preferably R qa Selected from -CH2OH; Preferably, Selected from The Q1 is optionally replaced by 1 to 3 R q replace; B is selected from Preferred 6. The compound according to claim 1 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the compound is selected from one of the structures shown in Table E.

7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition comprises 1 to 1500 mg of the compound according to any one of claims 1 to 6 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.

8. Use of the compound according to any one of claims 1 to 6 or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal for the preparation of a drug for treating and / or alleviating pain.

9. A method for treating or alleviating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 6, or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or cocrystal thereof, preferably 1-1500 mg, wherein the disease is preferably pain.